

STERIS CORP
Form 10-Q
February 08, 2013
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 10-Q
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

x

For the quarterly period ended December 31, 2012

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

o

For the transition period from _____ to _____

Commission File Number 1-14643

STERIS Corporation
(Exact name of registrant as specified in its charter)

Ohio
(State or other jurisdiction of
incorporation or organization)

34-1482024
(IRS Employer
Identification No.)

5960 Heisley Road,
Mentor, Ohio
(Address of principal executive offices)
440-354-2600

44060-1834
(Zip code)

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

Smaller Reporting Company

(Do not check if a smaller reporting company)

Edgar Filing: STERIS CORP - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of common shares outstanding as of January 31, 2013: 58,465,549

1

Table of Contents

STERIS Corporation and Subsidiaries
Form 10-Q
Index

	Page
<u>Part I—Financial Information</u>	
<u>Item 1.</u> <u>Financial Statements</u>	<u>3</u>
<u>Item 2.</u> <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>27</u>
<u>Item 3.</u> <u>Quantitative and Qualitative Disclosures About Market Risk</u>	<u>43</u>
<u>Item 4.</u> <u>Controls and Procedures</u>	<u>43</u>
<u>Part II—Other Information</u>	
<u>Item 1.</u> <u>Legal Proceedings</u>	<u>44</u>
<u>Item 1A.</u> <u>Risk Factors</u>	<u>46</u>
<u>Item 2.</u> <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>46</u>
<u>Item 6.</u> <u>Exhibits</u>	<u>47</u>
	<u>Signature</u> <u>48</u>

Table of Contents

PART 1—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

STERIS CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands)

	December 31, 2012 (Unaudited)	March 31, 2012
Assets		
Current assets:		
Cash and cash equivalents	\$ 155,887	\$ 150,821
Accounts receivable (net of allowances of \$9,511 and \$11,428, respectively)	248,021	280,324
Inventories, net	163,577	157,712
Deferred income taxes, net	16,235	43,211
Prepaid expenses and other current assets	38,413	19,815
Total current assets	622,133	651,883
Property, plant, and equipment, net	425,550	386,409
Goodwill and intangibles, net	709,950	337,784
Other assets	7,439	29,620
Total assets	\$ 1,765,072	\$ 1,405,696
Liabilities and equity		
Current liabilities:		
Accounts payable	\$ 78,169	\$ 83,188
Accrued payroll and other related liabilities	49,901	29,899
Accrued SYSTEM 1 Rebate Program and class action settlement	5,549	69,065
Accrued expenses and other	94,189	96,243
Total current liabilities	227,808	278,395
Long-term indebtedness	520,890	210,000
Deferred income taxes, net	37,917	42,703
Other liabilities	58,263	51,934
Total liabilities	\$ 844,878	\$ 583,032
Commitments and contingencies (see note 10)		
Serial preferred shares, without par value; 3,000 shares authorized; no shares issued or outstanding	—	—
Common shares, without par value; 300,000 shares authorized; 70,040 shares issued; 58,416 and 57,733 shares outstanding, respectively	240,850	244,091
Common shares held in treasury, 11,624 and 12,307 shares, respectively	(332,782) (350,718
Retained earnings	1,000,952	914,401
Accumulated other comprehensive income	10,100	13,627
Total shareholders' equity	919,120	821,401
Noncontrolling interest	1,074	1,263
Total equity	920,194	822,664
Total liabilities and equity	\$ 1,765,072	\$ 1,405,696

See notes to consolidated financial statements.

Table of ContentsSTERIS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share amounts)

(Unaudited)

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2012	2011	2012	2011
Revenues:				
Product	\$243,722	\$239,403	\$689,125	\$664,918
Service	136,683	115,812	384,561	351,643
Total revenues	380,405	355,215	1,073,686	1,016,561
Cost of revenues:				
Product	139,683	145,976	392,311	402,214
Service	87,600	71,233	237,880	210,107
Total cost of revenues	227,283	217,209	630,191	612,321
Gross profit	153,122	138,006	443,495	404,240
Operating expenses:				
Selling, general, and administrative	75,953	73,922	236,767	227,583
Research and development	10,415	9,196	29,579	26,867
Restructuring expenses	(386)) 1,164	(570)) 1,522
Total operating expenses	85,982	84,282	265,776	255,972
Income from operations	67,140	53,724	177,719	148,268
Non-operating expenses, net:				
Interest expense	4,207	3,005	10,586	9,083
Interest income and miscellaneous expense	(338)) (373)) (629)) (948)
Total non-operating expenses, net	3,869	2,632	9,957	8,135
Income before income tax expense	63,271	51,092	167,762	140,133
Income tax expense	15,174	17,443	49,166	48,189
Net income	\$48,097	\$33,649	\$118,596	\$91,944
Net income per common share				
Basic	\$0.82	\$0.58	\$2.04	\$1.57
Diluted	\$0.82	\$0.58	\$2.02	\$1.55
Cash dividends declared per common share outstanding	\$0.19	\$0.17	\$0.55	\$0.49

See notes to consolidated financial statements.

Table of ContentsSTERIS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(Unaudited)

	Three Months Ended		Nine Months Ended	
	December 31,		December 31,	
	2012	2011	2012	2011
Net income	\$48,097	\$33,649	118,596	91,944
Unrealized gain (loss) on available for sale securities	(3) 132	(20) (122
Amortization of pension and postretirement benefit plans costs, net of taxes	(184) (269) (543) (809
Change in cumulative foreign currency translation adjustment	2,269	(9,823) (2,964) (23,776
Total other comprehensive income (loss)	2,082	(9,960) (3,527) (24,707
Comprehensive income	\$50,179	\$23,689	\$115,069	\$67,237

See notes to consolidated financial statements.

Table of ContentsSTERIS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

	Nine Months Ended December	
	31,	
	2012	2011
Operating activities:		
Net income	\$118,596	\$91,944
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation, depletion, and amortization	48,508	46,288
Deferred income taxes	22,064	22,758
Share-based compensation expense	6,353	5,799
Loss on the disposal of property, plant, equipment, and intangibles, net	292	376
Other items	(211) (1,595
Changes in operating assets and liabilities, net of effects of acquisitions:		
Accounts receivable, net	52,889	20,019
Inventories, net	10,065	(2,404
Other current assets	(17,366) (6,954
Accounts payable	(13,397) (21,127
Accrued SYSTEM 1 Rebate Program and class action settlement	(63,516) (27,449
Accruals and other, net	16,659	(14,816
Net cash provided by operating activities	180,936	112,839
Investing activities:		
Purchases of property, plant, equipment, and intangibles, net	(63,878) (54,238
Proceeds from the sale of property, plant, equipment, and intangibles	29	—
Acquisition of business, net of cash acquired	(399,415) (22,269
Net cash used in investing activities	(463,264) (76,507
Financing activities:		
Proceeds from the issuance of long-term obligations	100,000	—
Proceeds under credit facilities, net	210,890	—
Deferred financing fees and debt issuance costs	(1,581) —
Repurchases of common shares	(7,893) (56,751
Cash dividends paid to common shareholders	(32,045) (28,751
Stock option and other equity transactions, net	14,517	3,749
Tax benefit from stock options exercised	2,161	816
Net cash provided by (used in) financing activities	286,049	(80,937
Effect of exchange rate changes on cash and cash equivalents	1,345	(4,624
Increase (decrease) in cash and cash equivalents	5,066	(49,229
Cash and cash equivalents at beginning of period	150,821	193,016
Cash and cash equivalents at end of period	\$155,887	\$143,787

See notes to consolidated financial statements.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

1. Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

STERIS Corporation, an Ohio corporation, develops, manufactures and markets infection prevention, contamination control, microbial reduction, and surgical and critical care support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental Customers throughout the world. As used in this Quarterly Report, STERIS Corporation and its subsidiaries together are called “STERIS,” the “Company,” “we,” “us,” or “our,” unless otherwise noted.

We operate in three reportable business segments: Healthcare, Life Sciences, and STERIS Isomedix Services (“Isomedix”). We describe our business segments in note 11 to our consolidated financial statements titled, “Business Segment Information.” Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:

Interim Financial Statements

We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.

These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2012 dated May 29, 2012. The Consolidated Balance Sheet at March 31, 2012 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

Principles of Consolidation

We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts.

Use of Estimates

We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these

estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2012 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2013.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

Recently Adopted Accounting Pronouncements

In June 2011, the FASB issued an accounting standard update titled "Presentation of Comprehensive Income," amending Accounting Standards Codification ASC Topic 220, "Comprehensive Income." This guidance requires that all non-owner changes in stockholders' equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. This guidance became effective retrospectively for the interim periods and annual periods beginning after December 15, 2011; however, the FASB agreed to an indefinite deferral of the reclassification requirement as defined in accounting standard update titled "Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income," issued in December 2011. As required by the standard, Consolidated Statements of Comprehensive Income have been presented. The adoption of this standard did not have an impact on our consolidated financial position, results of operations or cash flows.

In July 2012, the FASB issued an accounting standards update titled "Testing Indefinite-Lived Intangible Assets for Impairment," amending certain sections of Subtopic 350-30 Intangibles-Goodwill and Other-General Intangibles Other than Goodwill. This amended guidance allows an entity to first assess qualitative factors to determine if it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount. If based on its qualitative assessment an entity concludes it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, quantitative impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. The standards update is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. The anticipated adoption of this standard is not expected to impact our consolidated financial position, results of operations or cash flows.

Significant Accounting Policies

A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2012 dated May 29, 2012. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2012 with the exception of the estimates associated with the SYSTEM 1 Rebate Program and class action settlement.

SYSTEM 1 Rebate Program and Class Action Settlement

The SYSTEM 1 Rebate Program (the "Rebate Program") was initially recognized during the first quarter of fiscal 2011. The rebate portion of the Rebate Program was recognized as contra-revenue consistent with other returns and allowances offered to Customers. The estimated costs to facilitate the disposal of the returned SYSTEM 1 processors portion of the Rebate Program were recognized as cost of revenues. Both components are recorded as current liabilities. The key assumptions involved in the estimates associated with the Rebate Program included: the number and age of SYSTEM 1 processors eligible for rebates under the Rebate Program, the number of Customers that would elect to participate in the Rebate Program, the proportion of Customers that would choose each rebate option, and the estimated per unit costs of disposal.

The Rebate Program ended August 2, 2012. Through December 31, 2012, Customers have utilized or committed to utilize rebates totaling approximately \$66,600 on orders placed since the initiation of the Rebate Program. Additional Customer orders utilizing rebates are not anticipated although exceptions can be made at the discretion of the Company and existing orders may be modified or canceled by Customers. Remaining disposal costs are based on the actual costs experienced to date.

During the second quarter of fiscal 2013, we adjusted the liability related to the Rebate Program. The total pre-tax adjustment was \$21,500, of which \$20,400 was recorded as an increase to revenue for the Customer rebate portion, and \$1,100 was recorded as a reduction to cost of revenues related to the disposal portion of the liability. This adjustment resulted primarily from a lower number of eligible Customers electing to participate in the Rebate Program than previously estimated. The remaining recorded accrual is \$4,312 as of December 31, 2012.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

The SYSTEM 1 class action settlement was initially recognized during the third quarter of fiscal 2011. The claim submission deadline was December 31, 2012. As a result during the third quarter of fiscal 2013, we adjusted the liability related to the SYSTEM 1 class action settlement. The pretax adjustment of \$15,800, was recorded as a reduction to operating expenses. The remaining recorded accrual is \$1,237 as of December 31, 2012 and is based on actual claims submitted through December 31, 2012.

2. Restructuring

The following summarizes our restructuring plans announced in prior fiscal years. We recognize restructuring expenses as incurred. In addition, we assess the property, plant and equipment associated with the related facilities for impairment. Additional information regarding our restructuring plans is included in our Annual Report on Form 10-K for the year ended March 31, 2012 dated May 29, 2012.

Fiscal 2010 Restructuring Plan

During the fourth quarter of fiscal 2010 we adopted a restructuring plan primarily related to the transfer of the remaining operations in our Erie, Pennsylvania facility to the U.S. headquarters in Mentor, Ohio and the consolidation of our European Healthcare manufacturing operations into two central locations within Europe (the "Fiscal 2010 Restructuring Plan"). In addition, we rationalized certain products and eliminated certain positions.

Since the inception of the Fiscal 2010 Restructuring Plan, we have incurred pre-tax expenses totaling \$8,171 related to these actions, of which \$7,065 was recorded as restructuring expenses and \$1,106 was recorded in cost of revenues. We do not expect to incur any significant additional restructuring expenses related to this plan. These actions are intended to enhance profitability and improve efficiencies.

The following table summarizes our total pre-tax restructuring expenses for the third quarter of fiscal 2013 and fiscal 2012:

Three Months Ended December 31,	Fiscal 2010 Restructuring Plan	
	2012	2011 (1)
Severance and other compensation related costs	\$(386)	\$7
Asset impairment and accelerated depreciation	—	1,157
Lease termination obligation and other	—	3
Total restructuring charges	\$(386)	\$1,167

(1)Includes \$3 in charges recorded in cost of revenues on Consolidated Statements of Income for fiscal 2012.

The following table summarizes our total pre-tax restructuring expenses for the first nine months of fiscal 2013 and fiscal 2012:

Nine Months Ended December 31,	Fiscal 2010 Restructuring Plan		Fiscal 2008 Restructuring Plan		Total	
	2012	2011 (1)	2012	2011	2012	2011 (1)
Severance and other compensation related costs	\$(553)	\$(73)	\$—	\$—	\$(553)	\$(73)

Edgar Filing: STERIS CORP - Form 10-Q

Product rationalization	—	335	—	—	—	335		
Asset impairment and accelerated depreciation	(17) 1,341	—	—	(17) 1,341		
Lease termination obligation and other	—	3	—	(152)—	(149		
Total restructuring charges		\$ (570) \$ 1,606		\$ —	\$ (152) \$ (570) \$ 1,454

(1) Includes \$(68) in charges recorded in cost of revenues on Consolidated Statements of Income for fiscal 2012.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within "Accrued payroll and other related liabilities" and "Accrued expenses and other." The following table summarizes our liabilities related to these restructuring activities:

	Fiscal 2010 Restructuring Plan		Payments/ Impairments (2)	December 31, 2012
	March 31, 2012	Provision (1)		
Severance and termination benefits	\$659	\$(553)) \$326	\$432
Asset impairments and accelerated depreciation	—	(17)) 17	—
Lease termination obligations	947	—	(791)) 156
Other	76	—	(76)) —
Total	\$1,682	\$(570)) \$(524)) \$588

(1) Includes curtailment benefit of \$495 related to International defined benefit plan. Additional information is included in note 9, "Benefit Plans."

(2) Certain amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

3. Property, Plant and Equipment

Information related to the major categories of our depreciable assets is as follows:

	December 31, 2012	March 31, 2012
Land and land improvements (1)	\$36,129	\$33,099
Buildings and leasehold improvements	238,010	230,823
Machinery and equipment	318,912	301,665
Information systems	94,094	110,130
Radioisotope	233,564	210,899
Construction in progress (1)	43,396	22,811
Total property, plant, and equipment	964,105	909,427
Less: accumulated depreciation and depletion	(538,555)) (523,018)
Property, plant, and equipment, net	\$425,550	\$386,409

(1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

4. Business Acquisitions

United States Endoscopy Group, Inc.

In August 2012, we completed the acquisition of all the outstanding shares of capital stock of United States Endoscopy Group, Inc. ("US Endoscopy") pursuant to a Stock Purchase Agreement dated July 16, 2012 with US Endoscopy and its shareholders. The purchase price was approximately \$270,000, plus a working capital adjustment of \$2,145, which was paid during the third quarter of fiscal year 2013. In addition, we purchased all real estate used in the US Endoscopy business for approximately \$7,000, including properties owned by two US Endoscopy affiliates. We did not assume any existing debt in connection with the purchases. The purchases were financed by a combination of cash on hand and borrowings under our existing credit facility. US Endoscopy will be integrated into the Healthcare

segment.

10

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

The following table summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition date.

Cash	\$767	
Accounts receivable	8,291	
Inventory	7,228	
Property, plant and equipment	12,457	
Other assets	913	
Intangible assets	144,000	
Goodwill	111,261	
Total assets acquired	284,917	
Accounts payable	(2,167)
Other liabilities	(3,243)
Total liabilities assumed	(5,410)
Net assets acquired	\$279,507	

We recorded acquisition related costs of \$3,788, before tax, which are reported in selling, general and administrative expenses. We anticipate that the acquisition will qualify for a joint election tax benefit under Section 338(h)(10) of the Internal Revenue Code, which allows goodwill and intangibles to be fully deductible for tax purposes. The intangible assets acquired consist of trademarks, trade names and developed technologies, which will be amortized on a straight line basis over thirteen to fifteen years, with the exception of the US Endoscopy trade name which has an indefinite life.

The Consolidated Financial Statements include the operating results of US Endoscopy from the date of acquisition. Pro-forma results of operations for fiscal 2013 and 2012 periods have not been presented because the effects of the acquisition were not material to our financial results.

Spectrum Surgical Instruments Corp and Total Repair Express

In October 2012, we purchased two privately-owned businesses: Spectrum Surgical Instruments Corp ("Spectrum") and Total Repair Express ("TRE"), providers of surgical instrument repair services and instrument care products to hospitals and surgery centers in the United States. The aggregate purchase price of approximately \$110,000, including contingent consideration, was financed with borrowings under the existing credit facility. The instrument repair business will be integrated into the Healthcare business segment.

The following table summarizes the preliminary allocation of the purchase price to the net assets acquired in the Spectrum and TRE acquisitions, based on fair values at the acquisition date. The purchase price will be finalized after settlement of working capital adjustments and finalization of valuation analyses.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

Cash	\$424	
Accounts receivable	11,568	
Inventory	5,107	
Property, plant and equipment	5,145	
Other assets	295	
Intangible assets	41,500	
Goodwill	50,529	
Total assets acquired	114,568	
Accounts payable	(5,052))
Other liabilities	(3,460))
Total liabilities assumed	(8,512))
Net assets acquired	\$106,056	

We recorded acquisition related costs of \$1,880, before tax, which are reported in selling, general and administrative expenses. We anticipate that the acquisition of Spectrum will qualify for a joint election tax benefit under Section 338(h)(10) of the Internal Revenue Code, which allows goodwill and intangibles to be fully deductible for tax purposes. The intangible assets acquired consist of trademarks, customer relationships and non-complete arrangements, which will be amortized on a straight line basis over one to fifteen years.

The Consolidated Financial Statements include the operating results of Spectrum and TRE from the date of acquisition. Pro-forma results of operations for fiscal 2013 and 2012 periods have not been presented because the effects of the acquisition were not material to our financial results.

VTS Medical Systems, LLC

In December 2012, we purchased the remaining interests in our VTS Medical Systems, LLC ("VTS") joint venture. The joint venture began in fiscal 2009, and we increased our ownership of the joint venture to just under 50% during fiscal 2011. With this final investment, VTS is now a wholly-owned subsidiary of STERIS and will be integrated into the Healthcare business segment. We purchased the remaining interests for a total of approximately \$19,000, comprised of cash at closing and deferred cash payments to be paid over a ten year period.

We consolidated VTS for the first time in the third quarter of fiscal 2013. The following table summarizes the net assets included in the December 31, 2012 consolidated balance sheet including the preliminary allocation of the purchase price based on estimated fair values at the closing date. The consolidation had no impact on the consolidated statements of income for the period ended December 31, 2012. Valuations of the assets acquired and the equity interest held prior to the closing date are in process. Upon completion, the gain or loss on remeasurement to fair value of the equity interest will be recognized and the allocation of purchase price will be finalized.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

Cash	\$1,703	
Accounts receivable	294	
Inventory	4,280	
Property, plant and equipment	1,613	
Other assets	69	
Goodwill	34,435	
Total assets	42,394	
Accounts payable	(1,718))
Other liabilities	(1,896))
Total liabilities	(3,614))
Net assets consolidated	\$38,780	

5. Inventories, Net

Inventories, net are stated at the lower of cost or market. We use the last-in, first-out (“LIFO”) and first-in, first-out cost methods. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:

	December 31, 2012	March 31, 2012	
Raw materials	\$59,416	\$56,525	
Work in process	26,375	25,236	
Finished goods	105,389	109,422	
LIFO reserve	(15,783)	(18,158))
Reserve for excess and obsolete inventory	(11,820)	(15,313))
Inventories, net	\$163,577	\$157,712	

6. Debt

Indebtedness was as follows:

	December 31, 2012	March 31, 2012
Private Placement	\$310,000	\$210,000
Credit facility	210,890	—
Total long term debt	\$520,890	\$210,000

At the end of the third quarter, we had \$210,890 of borrowings that were outstanding under our credit facility. In October 2012, our credit facility was amended to increase the amount of credit available by an additional \$100,000, thereby increasing the maximum borrowing limit to \$400,000. During December 2012, we issued \$100,000 in senior notes in a private placement to certain institutional investors in an offering that was exempt from the registration

requirement of the Securities Act of 1933. Of the \$100,000 of notes, \$47,500 had a maturity of 10 years at an annual interest rate of 3.20%, an additional \$40,000 had a maturity of 12 years at an annual interest rate of 3.35%, and the remaining \$12,500 had a maturity of 15 years at an annual interest rate of 3.55%. These borrowings were used primarily for the repayment of existing credit facility debt. We issued another \$100,000 of notes to the same purchasers in early February 2013. With respect to the \$100,000 of notes issued in February 2013, \$47,500 had a maturity of 9 years and 10 months at an annual interest rate of 3.20%, an additional \$40,000 had

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

a maturity of 11 years and 10 months at an annual interest rate of 3.35%, and the remaining \$12,500 had a maturity of 14 years and 10 months at an annual interest rate of 3.55%.

Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2012 dated May 29, 2012.

7. Additional Consolidated Balance Sheet Information

Additional information related to our Consolidated Balance Sheets is as follows:

	December 31, 2012	March 31, 2012
Accrued payroll and other related liabilities:		
Compensation and related items	\$17,508	\$9,273
Accrued vacation/paid time off	8,282	6,583
Accrued bonuses	12,087	750
Accrued employee commissions	8,503	9,845
Other postretirement benefit obligations-current portion	3,256	3,255
Other employee benefit plans' obligations-current portion	265	193
Total accrued payroll and other related liabilities	\$49,901	\$29,899
Accrued expenses and other:		
Deferred revenues	\$47,763	\$51,412
Self-insured risk reserves-current portion	3,154	3,006
Accrued dealer commissions	8,211	9,171
Accrued warranty	12,799	11,189
Other	22,262	21,465
Total accrued expenses and other	\$94,189	\$96,243
Other liabilities:		
Self-insured risk reserves-long-term portion	\$8,786	\$8,786
Other postretirement benefit obligations-long-term portion	19,672	21,639
Defined benefit pension plans obligations-long-term portion	6,643	9,881
Other employee benefit plans obligations-long-term portion	4,639	4,486
Accrued long-term income taxes	12,254	1,925
Other	6,269	5,217
Total other liabilities	\$58,263	\$51,934

8. Income Tax Expense

Income tax expense includes United States federal, state and local, and foreign income taxes, and is based on reported pre-tax income. The effective income tax rates for the three-month periods ended December 31, 2012 and 2011 were 24.0% and 34.1%, respectively. The effective income tax rates for the nine-month periods ended December 31, 2012 and 2011 were 29.3% and 34.4%, respectively. During the first nine months of fiscal 2013, we benefited from higher projected income in lower rate tax jurisdictions, a large favorable discrete item adjustment due to the realization of a deduction related to the closure of our Swiss manufacturing operations, and other discrete item adjustments.

Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

As of March 31, 2012, we had \$1,527 in unrecognized tax benefits, of which \$1,242 would favorably impact the effective tax rate if recognized. As of December 31, 2012, we had \$10,884 in unrecognized tax benefits, of which \$10,599 would

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

favorably impact the effective tax rate if recognized. The increase in unrecognized tax benefits relates to a fiscal 2012 tax position. We believe that it is reasonably possible that unrecognized tax benefits could decrease by up to \$10,481 within 12 months of December 31, 2012, primarily as a result of settlements with tax authorities. As of December 31, 2012, we have recognized a liability for interest of \$1,305 and penalties of \$64.

We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2010 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2008. We remain subject to tax authority audits in various jurisdictions wherever we do business. We do not expect the results of these examinations to have a material adverse affect on our consolidated financial statements.

9. Benefit Plans

We provide defined benefit pension plans for certain current and former manufacturing and plant administrative personnel throughout the world as determined by collective bargaining agreements or employee benefit standards set at the time of acquisition of certain businesses. In addition to providing pension benefits to certain employees, we sponsor an unfunded postretirement welfare benefits plan for two groups of United States employees, including the same employees who receive pension benefits under the United States defined benefit pension plan. Benefits under this plan include retiree life insurance and retiree medical coverage, including prescription drug coverage. Additional information regarding our defined benefit pension plans and other postretirement benefits plan is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2012, dated May 29, 2012.

Components of the net periodic benefit cost for our defined benefit pension plans and other postretirement medical benefits plan were as follows:

	Defined Benefit Pension Plans				Other Postretirement Benefits Plan	
	U.S. Qualified		International		2012	2011
Three Months Ended December 31,	2012	2011	2012	2011	2012	2011
Service cost	\$37	\$51	\$21	\$114	\$—	\$—
Interest cost	523	609	19	66	217	248
Expected return on plan assets	(834)	(821)	(25)	(67)	—	—
Amortization of loss	333	267	—	—	181	106
Curtailement	—	—	(386)	—	—	—
Amortization of prior service cost	—	—	—	—	(816)	(816)
Net periodic benefit cost (income)	\$59	\$106	\$(371)	\$113	\$(418)	\$(462)
	Defined Benefit Pension Plans				Other Postretirement Benefits Plan	
	U.S. Qualified		International		2012	2011
Nine Months Ended December 31,	2012	2011	2012	2011	2012	2011
Service cost	\$112	\$154	\$63	\$341	\$—	\$—
Interest cost	1,569	1,828	56	198	650	743

Edgar Filing: STERIS CORP - Form 10-Q

Expected return on plan assets	(2,503)	(2,463)	(74)	(201)	—	—
Amortization of loss	1,000	799	—	—	544	319
Curtailment	—	—	(495)	—	—	—
Amortization of prior service cost	—	—	—	—	(2,447)	(2,447)
Net periodic benefit cost (income)	\$178	\$318	\$(450)	\$338	\$(1,253)	\$(1,385)

We contribute amounts to the defined benefit pension plans at least sufficient to meet the minimum requirements as stated in applicable employee benefit laws and local tax laws. We record liabilities for the difference between the fair value of the plan

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated postretirement benefit obligation for other postretirement benefits plans) on our accompanying Consolidated Balance Sheets.

10. Commitments and contingencies

We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse affect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.

As previously disclosed, we received a warning letter (the “warning letter”) from the FDA on May 16, 2008 regarding our SYSTEM 1® sterile processor and the STERIS 20 sterilant used with the processor (sometimes referred to collectively in the FDA letter and in this note 10 as the “device”). Among other matters, the warning letter included the FDA’s assertion that significant changes or modifications had been made in the design, components, method of manufacture, or intended use of the device beyond the FDA’s 1988 clearance, such that the FDA believed a new premarket notification submission (known within FDA regulations as a 510(k) submission) should have been made, and the assertion that our failure to make such a submission resulted in violations of applicable law. On July 30, 2008 (with an Addendum on October 9, 2008), we provided a detailed response contending that the assertions in the warning letter were not correct. On November 4, 2008, we received a letter from the FDA (dated November 3, 2008) in which the FDA stated without elaboration that, after reviewing our response, it disagreed with our position and that a new premarket notification submission was required. After discussions with the FDA regarding the November 3rd letter, we received an additional letter on November 6, 2008 from the FDA. The November 6th letter stated that the intent of the November 3rd letter was to inform us of the FDA’s preliminary disagreement with our response to the warning letter and, before finalizing a position, the FDA reiterated that it wanted to meet with us to discuss the Company’s response, issues related to the warning letter and next steps to resolve any differences between the Company and the FDA. We thereafter met with the FDA and, on January 20, 2009, we announced that we had submitted to the FDA a new liquid chemical sterilant processing system for 510(k) clearance, and we communicated to Customers that we would continue supporting the existing SYSTEM 1 installed base in the U.S. for at least a two year period from that date.

On December 3, 2009, the FDA provided a notice (“notice”) to healthcare facility administrators and infection control practitioners describing FDA's “concerns about the SYSTEM 1 Processor, components and accessories, and FDA recommendations.” In the notice, among other things, FDA stated its belief that the SYSTEM 1 device had been significantly modified, that FDA had not cleared or approved the modified device, and that FDA had not determined whether the SYSTEM 1 was safe or effective for its labeled claims. The notice further stated that use of a device that does not properly sterilize or disinfect a medical or surgical device poses risks to patients and users, including the transmission of pathogens, exposure to hazardous chemicals and may affect the quality and functionality of reprocessed instruments. The notice stated that FDA was aware of reports of malfunctions of the SYSTEM 1 that had the potential to cause or contribute to serious injuries to patients, such as infections, or injuries to healthcare staff, such as burns. Included in FDA's December 3, 2009 notice was a recommendation from FDA that if users had acceptable alternatives to meet sterilization and disinfection needs, they should transition to that alternative as soon as possible. After its December 3, 2009 notice, we engaged in extensive discussions with the FDA regarding a comprehensive resolution of this matter. On February 2, 2010, the FDA notified healthcare facility administrators and infection control practitioners that FDA's total recommended time period for transitioning from SYSTEM 1 in the U.S. was 18 months from that date.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

On April 5, 2010, we received FDA clearance of the new liquid chemical sterilant processing system (SYSTEM 1E). Also in April 2010 we reached agreement with the FDA on the terms of a consent decree (“Consent Decree”). On April 19, 2010, a Complaint and Consent Decree were filed in the U.S. District Court for the Northern District of Ohio, and on April 20, 2010, the Court approved the Consent Decree. In general, the Consent Decree addresses regulatory matters regarding SYSTEM 1, restricts further sales of SYSTEM 1 processors in the U.S., defines certain documentation and other requirements for continued service and support of SYSTEM 1 in the U.S., prohibits the sale of liquid chemical sterilization or disinfection products in the U.S. that do not have FDA clearance, describes various process and compliance matters, and defines penalties in the event of violation of the Consent Decree. The Consent Decree also provides that we may continue to support our Customers' use of SYSTEM 1 in the U.S., including the sale of consumables, parts and accessories and service for a transition period, not to extend beyond August 2, 2011 (later extended by FDA to August 2, 2012), subject to compliance with requirements for documentation of the Customer's need for continued support and other conditions and limitations (the “Transition Plan”). Our Transition Plan included the “SYSTEM 1 Rebate Program” (the “Rebate Program”). In April 2010, we began to offer rebates to qualifying Customers. Generally, U.S. Customers that purchased SYSTEM 1 processors directly from us or who were users of SYSTEM 1 at the time the Rebate Program was introduced and who returned their units had the option of either a pro-rated cash rebate or a rebate toward the future purchase of new STERIS capital equipment (including SYSTEM 1E) or consumable products. In addition, we provided credits for the return of SYSTEM 1 consumables in unbroken packaging and within shelf life and for the unused portion of SYSTEM 1 service contracts. The Rebate Program ended August 2, 2012. Through December 31, 2012, Customers have utilized or committed to utilize rebates totaling approximately \$66,600 on orders placed since the initiation of the Rebate Program. Additional Customer orders utilizing rebates are not anticipated although exceptions can be made at the discretion of the Company and existing orders may be modified or canceled by Customers. Remaining disposal costs are based on the actual costs experienced to date. During the second quarter of fiscal 2013, we adjusted the liability related to the Rebate Program. The total pre-tax adjustment was \$21,500, of which \$20,400 was recorded as an increase to revenue for the Customer Rebate portion, and \$1,100 was recorded as a reduction to cost of revenues related to the disposal portion of the liability. This adjustment resulted primarily from a lower number of eligible Customers electing to participate in the Rebate Program than previously estimated. The remaining recorded accrual is \$4,312 as of December 31, 2012.

The Consent Decree has defined the resolution of a number of issues regarding SYSTEM 1, and we believe our actions with respect to SYSTEM 1, including the Transition Plan, were and are not recalls, corrections or removals under FDA regulations. However, there is no assurance that these or other claims will not be brought or that judicial, regulatory, administrative or other legal or enforcement actions, notices or remedies will not be pursued, or that action will not be taken in respect of the Consent Decree, the Transition Plan, SYSTEM 1, or otherwise with respect to regulatory or compliance matters, as described in this note 10 and in various portions of Item 1A. of Part I of our Annual Report on Form 10-K for the year ended March 31, 2012 dated May 29, 2012.

In December of 2010, we began shipping SYSTEM 1E units, after having received FDA clearance for the SYSTEM 1E chemical indicator, which is used in conjunction with the SYSTEM 1E. We also submitted a 510(k) to FDA for an optional spore-based indicator strip for use with SYSTEM 1E. Thereafter, as a result of discussions with FDA, we filed a de novo submission requesting classification of this strip in accordance with Section 513(f)(2) of the Federal Food Drug & Cosmetic Act. The de novo process is part of the initial classification for new devices. This spore-based monitoring strip received FDA clearance on March 30, 2012. This new clearance does not affect the prior clearance of the SYSTEM 1E processor or the SYSTEM 1E chemical indicator.

On February 5, 2010, a complaint was filed by a Customer that claimed to have purchased two SYSTEM 1 devices from STERIS, Physicians of Winter Haven LLC d/b/a Day Surgery Center v. STERIS Corp., Case

No. 1:1-cv-00264-CAB (N.D. Ohio). The complaint alleged statutory violations, breaches of various warranties, negligence, failure to warn, and unjust enrichment and Plaintiff sought class certification, damages, and other legal and equitable relief including, without limitation, attorneys' fees and an order requiring STERIS to replace, recall or adequately repair the product and/or to take appropriate regulatory action. On February 7, 2011 we entered into a settlement agreement in which we agreed, among other things, to provide various categories of economic relief for members of the settlement class and not object to plaintiff's counsel's application to the court for attorneys' fees and expenses up to a specified amount. Certification of a settlement class was approved and final approval of the settlement was given by the court in the first quarter of fiscal 2012. During the third quarter of fiscal 2011, we recorded in operating expenses a pre-tax charge of approximately \$19,796 related to the settlement of these proceedings. The assumptions regarding the amount of this charge included, among others, the portion of class members participating in the settlement and their choice of the categories of economic relief available for such members. The claim

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

submission deadline was December 31, 2012. As a result, during the third quarter of fiscal 2013, we adjusted the liability related to the SYSTEM 1 class action settlement. The pretax adjustment of \$15,800, was recorded as a reduction to operating expenses. The remaining recorded accrual is \$1,237 as of December 31, 2012 and based on actual claims submitted through December 31, 2012.

On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results.

Other civil, criminal, regulatory or other proceedings involving our products or services also could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially affect our business, performance, prospects, value, financial condition, and results of operations.

For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the fiscal year ended March 31, 2012: "Business - Information with respect to our Business in General - Government Regulation", and the "Risk Factor" titled "We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters, including the Warning Letter and Consent Decree" and the "Risk Factor" titled "Compliance with the Consent Decree may be more costly and burdensome than anticipated."

From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized.

We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates.

Additional information regarding our contingencies is included in Item 7 of Part II titled, "Management's Discussion and Analysis of Financial Conditions and Results of Operations," of our Annual Report on Form 10-K for the year ended March 31, 2012 dated May 29, 2012, and in Item 1 of Part II of this Form 10-Q titled, "Legal Proceedings."

11. Business Segment Information

We operate and report in three business segments: Healthcare, Life Sciences, and Isomedix. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs.

Our Healthcare segment manufactures and sells capital equipment, accessory, consumable, and service solutions to healthcare providers, including acute care hospitals and surgery centers. These solutions aid our Customers in improving the safety, quality, and productivity of their surgical, sterile processing, gastrointestinal, and emergency environments.

Our Life Sciences segment manufactures and sells engineered capital equipment, formulated cleaning chemistries, and service solutions to pharmaceutical companies, and private and public research facilities around the globe.

Our Isomedix segment operates through a network of facilities located in North America. We sell a comprehensive array of materials processing services using gamma irradiation, and ethylene oxide ("EO") technologies. We provide microbial reduction services based on Customer specifications to companies that supply products to the healthcare, industrial, and consumer products industries.

Operating income (loss) for each segment is calculated as the segment's gross profit less direct expenses and indirect cost allocations, which results in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare segment is responsible for the management of all but one manufacturing facility and uses standard cost to sell products to the Life Sciences segment. Corporate and other includes the gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and postretirement benefits.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

The accounting policies for reportable segments are the same as those for the consolidated Company. For the three and nine month periods ended December 31, 2012, revenues from a single Customer did not represent ten percent or more of any reportable segment's revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2012, dated with the SEC on May 29, 2012.

Financial information for each of our segments is presented in the following tables:

	Three Months Ended December		Nine Months Ended December	
	31,		31,	
	2012	2011	2012	2011
Revenues:				
Healthcare (1)	\$271,096	\$259,055	\$757,430	\$725,455
Life Sciences	65,043	55,892	180,116	167,675
Isomedix	43,392	39,615	133,732	121,617
Total reportable segments	379,531	354,562	1,071,278	1,014,747
Corporate and other	874	653	2,408	1,814
Total revenues	\$380,405	\$355,215	\$1,073,686	\$1,016,561
Operating income:				
Healthcare (2)	\$45,478	\$33,951	\$110,355	\$88,213
Life Sciences	12,798	10,297	35,201	30,820
Isomedix	11,103	11,750	39,348	35,924
Total reportable segments	69,379	55,998	184,904	154,957
Corporate and other	(2,239)	(2,274)	(7,185)	(6,689)
Total operating income	\$67,140	\$53,724	\$177,719	\$148,268

(1) Includes an increase of \$20,400 in the fiscal 2013 nine months ended December 31, 2012 period, resulting from the SYSTEM 1 Rebate Program.

(2) Includes an increase of \$15,800 in the fiscal 2013 three months ended December 31, 2012 period and \$37,300 in the fiscal 2013 nine months ended December 31, 2012 period, resulting from SYSTEM 1 Rebate Program and class action settlement.

Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments.

"Corporate and other" includes assets directly attributable to the Defense and Industrial business unit, as well as certain unallocated amounts related to being a publicly traded company. Total assets associated with the Healthcare segment have increased substantially during the first nine months of fiscal 2013, as a result of several business acquisitions as described in Note 4 to our consolidated financial statements titled, "Business Acquisitions".

Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.

Total assets for the periods as of December 31, 2012 and March 31, 2012 are presented in the following table:

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

	December 31, 2012	March 31, 2012
Assets:		
Healthcare and Life Sciences	\$1,366,871	\$1,024,786
Isomedix	395,557	378,506
Total reportable segments	1,762,428	1,403,292
Corporate and other	2,644	2,404
Total assets	\$1,765,072	\$1,405,696

12. Common Shares

We calculate basic earnings per common share based upon the weighted average number of common shares outstanding. We calculate diluted earnings per share based upon the weighted average number of common shares outstanding plus the dilutive effect of common share equivalents calculated using the treasury stock method. The following is a summary of common shares and common share equivalents outstanding used in the calculations of basic and diluted earnings per share:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2012	2011	2012	2011
Denominator (shares in thousands):				
Weighted average common shares outstanding—basic	58,425	57,782	58,200	58,594
Dilutive effect of common share equivalents	547	455	492	646
Weighted average common shares outstanding and common share equivalents—diluted	58,972	58,237	58,692	59,240

Options to purchase the following number of common shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the common shares during the periods, so including these options would be anti-dilutive:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2012	2011	2012	2011
(shares in thousands)				
Number of common share options	569	1,040	787	644

13. Repurchases of Common Shares

During the first nine months of fiscal 2013, we repurchased 204,349 of our common shares as part of our Board authorized repurchase program and obtained 50,852 of our common shares in connection with stock based compensation award programs. At December 31, 2012, \$111,630 of STERIS common shares remained authorized for repurchase pursuant to the most recent Board approved repurchase authorization (the March 2008 Board Authorization). Also, 11,624,076 common shares were held in treasury at December 31, 2012.

14. Share-Based Compensation

We maintain a long-term incentive plan that makes available common shares for grants, at the discretion of the Compensation Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, and stock appreciation rights. Stock options provide the right to purchase our common shares at the market price on the date of grant, subject to the terms of the option plans and agreements. Generally, one-fourth of the stock options granted become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally may cliff vest after a three or four year period or vest in tranches of one-fourth of the number

20

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

granted for each full year of employment after the grant date. As of December 31, 2012, 3,858,299 shares remained available for grant under the long-term incentive plan.

The fair value of share-based compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee's compensation and benefits.

The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2013 and fiscal 2012:

	Fiscal 2013	Fiscal 2012
Risk-free interest rate	1.21	% 2.41%
Expected life of options	5.79 years	5.65 years
Expected dividend yield of stock	2.15	% 1.78%
Expected volatility of stock	31.24	% 29.78%

The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 1.83% and 2.08% was applied in fiscal 2013 and 2012, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually.

A summary of share option activity is as follows:

	Number of Options	Weighted Average Exercise Price	Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2012	3,312,602	\$27.16		
Granted	300,440	30.26		
Exercised	(608,195)) 23.90		
Forfeited	(5,933)) 30.12		
Canceled	(3,970)) 19.95		
Outstanding at December 31, 2012	2,994,944	\$28.13	5.42	years \$20,158
Exercisable at December 31, 2012	2,226,762	\$27.18	4.43	years \$16,914

We estimate that 757,650 of the non-vested stock options outstanding at December 31, 2012 will ultimately vest.

The aggregate intrinsic value in the table above represents the total pre-tax difference between the \$34.73 closing price of our common shares on December 31, 2012 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of our common shares.

The total intrinsic value of stock options exercised during the first nine months of fiscal 2013 and fiscal 2012 was \$5,603 and \$2,111, respectively. Net cash proceeds from the exercise of stock options were \$14,517 and \$3,749 for the first nine months of fiscal 2013 and fiscal 2012, respectively. The tax benefit from stock option exercises was \$2,161 and \$816 for the first nine months of fiscal 2013 and fiscal 2012, respectively.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

The weighted average grant date fair value of stock option grants was \$7.32 and \$9.31 for the first nine months of fiscal 2013 and fiscal 2012, respectively.

Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of December 31, 2012 and 2011 was \$888 and \$763, respectively. The fair value of outstanding SARs is revalued at each reporting date and the related liability and expense are adjusted appropriately.

A summary of the non-vested restricted share activity is presented below:

	Number of Restricted Shares	Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2012	533,027	\$32.10
Granted	329,790	31.45
Vested	(104,769) 25.11
Canceled	(11,737) 33.13
Non-vested at December 31, 2012	746,311	\$32.78

Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares that vested during the first nine months of fiscal 2013 was \$2,631.

Cash settled restricted share units carry generally the same terms and vesting requirements as stock settled restricted share units except that they are settled in cash upon vesting and therefore, are classified as liabilities. The fair value of outstanding cash-settled restricted share units as of December 31, 2012 and 2011 was \$1,208 and \$1,244, respectively. The fair value of each cash-settled restricted share unit is revalued at each reporting date and the related liability and expense are adjusted appropriately.

As of December 31, 2012, there was a total of \$17,451 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 2.63 years.

15. Financial and Other Guarantees

We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.

Changes in our warranty liability during the first nine months of fiscal 2013 were as follows:

Balance, March 31, 2012	\$11,189	
Warranties issued during the period	13,177	
Settlements made during the period	(11,567)
Balance, December 31, 2012	\$12,799	

We also sell product maintenance contracts to our Customers. These contracts range in terms from one to five years and require us to maintain and repair the product over the maintenance contract term. We initially record amounts due from Customers under these contracts as a liability for deferred service contract revenue on the accompanying Consolidated Balance

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

Sheets within "Accrued expenses and other." The liability recorded for such deferred service revenue was \$38,549 and \$43,252 as of December 31, 2012 and March 31, 2012, respectively. Such deferred revenue is then amortized on a straight-line basis over the contract term and recognized as service revenue on our accompanying Consolidated Statements of Income. The activity related to the liability for deferred service contract revenues is excluded from the table presented above.

16. Forward and Swap Contracts

From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We also enter into commodity swap contracts to hedge price changes in commodities that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At December 31, 2012, we held foreign currency forward contracts to buy 79.7 million Mexican pesos and 12.5 million Canadian dollars. At December 31, 2012, we held commodity swap contracts to buy 190,000 pounds of nickel.

Balance Sheet Location	Asset Derivatives		Liability Derivatives	
	Fair Value at December 31, 2012	Fair Value at March 31, 2012	Fair Value at December 31, 2012	Fair Value at March 31, 2012
Prepaid & Other	\$—	\$12	\$—	\$—
Accrued expenses and other	\$—	\$—	\$358	\$863

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:

	Location of gain (loss) recognized in income	Amount of gain (loss) recognized in income	
		Nine Months Ended December 31, 2012	2011
Foreign currency forward contracts	Selling, general and administrative	\$24	\$(2,122)
Commodity swap contracts	Cost of revenues	\$(211)	\$(1,371)

17. Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at December 31, 2012 and March 31, 2012:

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

	Carrying Value		Fair Value Measurements at December 31, 2012 and March 31, 2012 Using					
			Quoted Prices in Active Markets for Identical Assets Level 1		Significant Other Observable Inputs Level 2		Significant Unobservable Inputs Level 3	
	December 31	March 31	December 31	March 31	December 31	March 31	December 31	March 31
Assets:								
Cash and cash equivalents	\$ 155,887	\$ 150,821	\$ 155,887	\$ 150,821	\$—	\$—	\$—	\$—
Forward and swap contracts (1)	—	12	—	—	—	12	—	—
Investments (2)	2,982	3,032	2,982	3,032	—	—	—	—
Liabilities:								
Forward and swap contracts (1)	\$358	\$863	\$—	\$—	\$358	\$863	\$—	\$—
Deferred compensation plans (2)	3,062	3,032	3,062	3,032	—	—	—	—
Long term debt (3)	520,890	210,000	—	—	560,971	243,999	—	—
Contingent consideration obligations (4)	7,842	6,953	—	—	—	—	7,842	6,953

(1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.

We maintain a domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the (2) plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees making deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)).

(3) We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.

Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and (4) captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2012 are summarized as follows:

	Contingent Consideration
Balance at March 31, 2012	\$6,953
Additions	1,250
Settlements	(9)
Foreign currency translation adjustments (1)	(352)

Balance at December 31, 2012	\$7,842
(1) Reported in other comprehensive income (loss).	

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2012 and 2011

(dollars in thousands, except per share amounts)

18. Subsequent Events

We have evaluated subsequent events through the date the financial statements were filed with the SEC, noting no events that require adjustment of, or disclosure in, the consolidated financial statements for the period ended December 31, 2012, except for the issuance of long term notes as described in note 6 to our consolidated financial statements titled, "Debt". These financial statements should be read in conjunction with the consolidated financial statements and related notes included in our 2012 Annual Report on Form 10-K dated May 29, 2012.

Table of Contents

Report of Independent Registered Public Accounting Firm

Board of Directors and Shareholders
STERIS Corporation

We have reviewed the consolidated balance sheet of STERIS Corporation and subsidiaries (the "Company") as of December 31, 2012, the related consolidated statements of income for the three-month and nine-month periods ended December 31, 2012 and 2011, the consolidated statements of comprehensive income for the three-month and nine-month periods ended December 31, 2012 and 2011, and consolidated statements of cash flows for the nine-month periods ended December 31, 2012 and 2011. These financial statements are the responsibility of the Company's management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the consolidated interim financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of STERIS Corporation and subsidiaries as of March 31, 2012, and the related consolidated statements of income, stockholders' equity, and cash flows for the year then ended not presented herein, and in our report dated May 29, 2012, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of March 31, 2012 is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/s/ Ernst & Young LLP

Cleveland, Ohio
February 8, 2013

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

In Management's Discussion and Analysis of Financial Condition and Results of Operations (the "MD&A"), we explain the general financial condition and the results of operations for STERIS including:

- what factors affect our business;
- what our earnings and costs were in each period presented;
- why those earnings and costs were different from prior periods;
- where our earnings came from;
- how this affects our overall financial condition;
- what our expenditures for capital projects were;
- where cash will come from to fund future debt principal repayments, growth outside of core operations, repurchase common shares, pay cash dividends and fund future working capital needs.

As you read the MD&A, it may be helpful to refer to information in our consolidated financial statements, which present the results of our operations for the third quarter and first nine months of fiscal 2013 and fiscal 2012. It may also be helpful to read the MD&A in our Annual Report on Form 10-K for the year ended March 31, 2012, dated May 29, 2012. In the MD&A, we analyze and explain the period-over-period changes in the specific line items in the Consolidated Statements of Income. Our analysis may be important to you in making decisions about your investments in STERIS.

Financial Measures

In the following sections of the MD&A, we may, at times, refer to financial measures that are not required to be presented in the consolidated financial statements under U.S. GAAP. We sometimes use the following financial measures in the context of this report: backlog; debt-to-total capital; net debt-to-total capital; and days sales outstanding. We define these financial measures as follows:

• **Backlog** – We define backlog as the amount of unfilled capital equipment purchase orders at a point in time. We use this figure as a measure to assist in the projection of short-term financial results and inventory requirements.

• **Debt-to-total capital** – We define debt-to-total capital as total debt divided by the sum of total debt and shareholders' equity. We use this figure as a financial liquidity measure to gauge our ability to borrow and fund growth.

• **Net debt-to-total capital** – We define net debt-to-total capital as total debt less cash ("net debt") divided by the sum of net debt and shareholders' equity. We also use this figure as a financial liquidity measure to gauge our ability to borrow and fund growth.

• **Days sales outstanding ("DSO")** – We define DSO as the average collection period for accounts receivable. It is calculated as net accounts receivable divided by the trailing four quarters' revenues, multiplied by 365 days. We use this figure to help gauge the quality of accounts receivable and expected time to collect.

We, at times, may also refer to financial measures which are considered to be "non-GAAP financial measures" under SEC rules. We have presented these financial measures because we believe that meaningful analysis of our financial performance is enhanced by an understanding of certain additional factors underlying that performance. These financial measures should not be considered an alternative to measures required by accounting principles generally accepted in the United States. Our calculations of these measures may differ from calculations of similar measures used by other companies and you should be careful when comparing these financial measures to those of other

companies. Additional information regarding these financial measures, including reconciliations of each non- GAAP financial measure, is available in the subsection of MD&A titled, "Non-GAAP Financial Measures."

Revenues – Defined

As required by Regulation S-X, we separately present revenues generated as either product revenues or service revenues on our Consolidated Statements of Income for each period presented. When we discuss revenues, we may, at times, refer to revenues summarized differently than the Regulation S-X requirements. The terminology, definitions, and applications of terms that we use to describe revenues may be different from terms used by other companies. We use the following terms to describe revenues:

Table of Contents

Revenues – Our revenues are presented net of sales returns and allowances.

Product Revenues – We define product revenues as revenues generated from sales of consumable and capital equipment products.

Service Revenues – We define service revenues as revenues generated from parts and labor associated with the maintenance, repair, and installation of our capital equipment, instrument repair services, and revenues generated from contract sterilization offered through our Isomedix segment.

Capital Revenues – We define capital revenues as revenues generated from sales of capital equipment, which includes steam sterilizers, low temperature liquid chemical sterilant processing systems, including SYSTEM 1 and 1E, washing systems, VHP® technology, water stills, and pure steam generators; surgical lights and tables; and integrated OR.

Consumable Revenues – We define consumable revenues as revenues generated from sales of the consumable family of products, which includes SYSTEM 1 and 1E consumables, V-Pro consumables, gastrointestinal endoscopy devices and support accessories, sterility assurance products, skin care products, cleaning consumables, and surgical instruments.

Recurring Revenues – We define recurring revenues as revenues generated from sales of consumable products and service revenues.

General Company Overview and Executive Summary

Our mission is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products, and services. Our dedicated employees around the world work together to supply a broad range of solutions by offering a combination of capital equipment, consumables, and services to healthcare, pharmaceutical, industrial, and governmental Customers. The bulk of our revenues are derived from the healthcare and pharmaceutical industries. Much of the growth in these industries is driven by the aging of the population throughout the world, as an increasing number of individuals are entering their prime healthcare consumption years, and is dependent upon advancement in healthcare delivery, acceptance of new technologies, government policies, and general economic conditions. In addition, each of our core industries is experiencing specific trends that could increase demand. Within healthcare, there is increased concern regarding the level of hospital-acquired infections around the world. The pharmaceutical industry has been impacted by increased FDA scrutiny of cleaning and validation processes, mandating that manufacturers improve their processes. The aging population increases the demand for medical procedures, which increases the consumption of single use medical devices and surgical kits processed by our Isomedix segment.

Beyond our core markets, infection-control issues are a growing global concern, and emerging threats are prominent in the news. We are actively pursuing new opportunities to adapt our proven technologies to meet the changing needs of the global marketplace.

In August 2012, we acquired all the outstanding shares of privately-owned United States Endoscopy Group, Inc. ("US Endoscopy") for approximately \$270 million plus a working capital adjustment of \$2.1 million, which was paid during the third quarter of fiscal year 2013. In addition, we purchased all real estate used in the US Endoscopy business for approximately \$7 million, including properties owned by two US Endoscopy affiliates. The business will be integrated into the Healthcare segment.

In October 2012, we purchased two privately-owned businesses: Spectrum Surgical Instruments Corp ("Spectrum") and Total Repair Express ("TRE"), providers of surgical instrument repair services and instrument care products to hospitals and surgery centers in the United States. The aggregate purchase price of approximately \$110 million, including contingent consideration, was financed with borrowings under our existing credit facility. The instrument repair business will be integrated into the Healthcare segment.

In December 2012, we purchased the remaining interests in our VTS Medical Systems, LLC ("VTS") joint venture. The joint venture began in fiscal 2009, and we increased our ownership of the joint venture to just under 50% during fiscal 2011. With this final investment, VTS is now a wholly-owned subsidiary and will be integrated into the Healthcare segment. We purchased the remaining interests for a total of approximately \$19.0 million, comprised of

cash at closing and deferred cash payments to be paid over a ten year period.

Healthcare revenues for the third quarter and first nine months of fiscal 2013 include \$35.7 million and \$45.9 million, respectively, as a result of these acquisitions.

Fiscal 2013 third quarter revenues were \$380.4 million representing an increase of 7.1% over the fiscal 2012 third quarter revenues of \$355.2 million. The increase of 7.1% is primarily from an increase in both service and consumable revenues as a result of recent business acquisitions. This increase was partially offset by the expected post-transition decline in SYSTEM 1E unit sales and the decline in SYSTEM 1 consumable volumes. Fiscal 2013 first nine months revenues were \$1,073.7 million

Table of Contents

representing an increase of 5.6% over the first nine months of fiscal 2012 revenues of \$1,016.6 million. This increase includes the fiscal 2013 second quarter SYSTEM 1 Rebate Program adjustment of \$20.4 million and the impact of recent acquisitions. Excluding the positive impact of the adjustment related to the SYSTEM 1 Rebate Program made during the second quarter, adjusted revenues were \$1,053.3 million for the first nine months of fiscal 2013 (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). Adjusted revenues for the first nine months of fiscal 2013 increased 3.6% compared to the first nine months of fiscal 2012, reflecting growth in both service and consumable revenues as a result of recent business acquisitions, partially offset by the expected post-transition decline in SYSTEM 1E unit sales and the decline in SYSTEM 1 consumable volumes.

Fiscal 2013 third quarter gross margin percentage was 40.3% compared with 38.9% for the fiscal 2012 third quarter. This increase was driven primarily by recent acquisitions, favorable pricing and product mix. For fiscal 2013, the first nine months of gross margin percentage was 41.3% compared with 39.8% for the first nine months of fiscal 2012. The primary driver of the increase in gross margin percentage for the first nine months was the positive impact of the \$21.5 million SYSTEM 1 Rebate Program adjustment during the fiscal 2013 second quarter. The adjusted gross margin percentage for the first nine months of 2013 was 40.1% compared to 39.8% in the first nine months of fiscal 2012 (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). This increase was attributable to acquisitions, favorable pricing and favorable foreign currency impact. The SYSTEM 1 and 1E transition continued to negatively impact gross margins relative to prior periods.

Fiscal 2013 third quarter operating income was \$67.1 million, an increase of 25.0% over the fiscal 2012 third quarter operating income of \$53.7 million. Fiscal 2013 first nine months operating income was \$177.7 million representing an increase of 19.9% compared to the fiscal 2012 first nine months operating income of \$148.3 million. The primary drivers of the increase in operating income were the positive impact of the \$21.5 million SYSTEM 1 Rebate Program adjustment recorded in the fiscal 2013 second quarter and the \$15.8 million SYSTEM 1 class action settlement adjustment recorded during the fiscal 2013 third quarter. Excluding the SYSTEM 1 class action settlement adjustment made in the fiscal 2013 third quarter, adjusted operating income was \$51.3 million in the fiscal 2013 third quarter, a decrease of 4.4% over the fiscal 2012 third quarter operating income of \$53.7 million, driven primarily by the declines in SYSTEM 1 consumable volumes and SYSTEM 1E unit sales and expenses related to the recent acquisitions (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). Adjusted operating income during the first nine months of fiscal 2013 was \$140.4 million, a decrease of 5.3% compared to the first nine months of fiscal 2012, driven primarily by the declines in SYSTEM 1 consumable volumes and SYSTEM 1E unit sales and expenses related to the recent acquisitions (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). Cash flows from operations were \$180.9 million and free cash flow was \$117.1 million in the first nine months of fiscal 2013 compared to cash flows from operations of \$112.8 million and free cash flow of \$58.6 million in the first nine months of fiscal 2012, reflecting a decrease in cash needed to fund operating assets and liabilities, and the cash benefit from a tax deduction related to the closure of our Swiss manufacturing operations (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). Our debt-to-total capital ratio was 36.2% at December 31, 2012 and 20.4% at March 31, 2012. During the first nine months of fiscal 2013, we declared and paid quarterly cash dividends of \$0.55 per common share.

Additional information regarding our financial performance during the fiscal third quarter and first nine months of 2013 is included in the subsection below titled "Results of Operations."

Matters Affecting Comparability

International Operations. Since we conduct operations outside of the United States using various foreign currencies, our operating results are impacted by foreign currency movements relative to the U.S. dollar. During the third quarter

of fiscal 2013, our revenues were unfavorably impacted by \$0.4 million, or 0.1%, and income before taxes was unfavorably impacted by \$0.9 million, or 1.4%, as a result of foreign currency movements relative to the U.S. dollar. During the first nine months of fiscal 2013, our revenues were unfavorably impacted by \$7.7 million, or 0.7%, and income before taxes was favorably impacted by \$4.2 million, or 2.6%, as a result of foreign currency movements relative to the U.S. dollar.

NON-GAAP FINANCIAL MEASURES

We, at times, refer to financial measures which are considered to be “non-GAAP financial measures” under SEC rules. We, at times, also refer to our results of operations excluding certain transactions or amounts that are non-recurring or are not indicative of future results, in order to provide meaningful comparisons between the periods presented.

Table of Contents

These non-GAAP financial measures are not intended to be, and should not be, considered separately from or as an alternative to the most directly comparable GAAP financial measures.

These non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision-making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.

We believe that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures and the reconciliation to the corresponding GAAP financial measures, provide the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

We define free cash flow as net cash provided by operating activities as presented in the Consolidated Statements of Cash Flows less purchases of property, plant, equipment, and intangibles plus proceeds from the sale of property, plant, equipment, and intangibles, which are also presented in the Consolidated Statements of Cash Flows. We use this as a measure to gauge our ability to fund future debt principal repayments, growth outside of core operations, repurchase common shares, and pay cash dividends. The following table summarizes the calculation of our free cash flow for the nine month periods ended December 31, 2012 and 2011:

(dollars in thousands)	Nine Months Ended December 31,	
	2012	2011
Net cash flows provided by operating activities	\$180,936	\$112,839
Purchases of property, plant, equipment and intangibles, net	(63,878)	(54,238)
Proceeds from the sale of property, plant, equipment and intangibles	29	—
Free cash flow	\$117,087	\$58,601

To supplement our financial results presented in accordance with U.S. GAAP, we have sometimes referred to certain measures of revenues, gross profit, gross profit percentage, and the Healthcare segment results of operations in the section of MD&A titled, "Results of Operations" excluding the impact of adjustments recorded in connection with the SYSTEM 1 Rebate Program and the SYSTEM 1 class action settlement in the third quarter and first nine months of fiscal 2013. These items had a significant impact on the fiscal 2013 measures and the corresponding trend in each of these measures. We provide adjusted measures to give the reader a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. These measures are used by management and the Board of Directors in making comparisons to our historical operating results and analyzing the underlying performance of our operations. The tables below provide a reconciliation of each of these measures to its most directly comparable GAAP financial measure.

(dollars in thousands)	Three Months Ended December 31,		Nine Months Ended December 31,	
	2012	2011	2012	2011
Reported revenues	\$380,405	\$355,215	\$1,073,686	\$1,016,561
Impact of the SYSTEM 1 Rebate Program	—	—	(20,400)	—
Adjusted revenues	\$380,405	\$355,215	\$1,053,286	\$1,016,561
Reported capital equipment revenues	\$147,068	\$165,290	\$435,162	\$439,134
Impact of the SYSTEM 1 Rebate Program	—	—	(20,400)	—
Adjusted capital equipment revenues	\$147,068	\$165,290	\$414,762	\$439,134
Reported United States revenues	\$281,411	\$263,540	\$815,604	\$766,011
Impact of the SYSTEM 1 Rebate Program	—	—	(20,400)	—
Adjusted United States Revenues	\$281,411	\$263,540	\$795,204	\$766,011

Edgar Filing: STERIS CORP - Form 10-Q

Reported Healthcare revenues	\$271,096	\$259,055	\$757,430	\$725,455
------------------------------	-----------	-----------	-----------	-----------

30

Table of Contents

Impact of the SYSTEM 1 Rebate Program	—	—	(20,400) —	
Adjusted Healthcare revenues	\$271,096	\$259,055	\$737,030	\$725,455	
Healthcare capital revenues	\$119,471	\$144,366	\$366,840	\$378,335	
Impact of SYSTEM 1 Rebate Program	—	—	(20,400) —	
Adjusted Healthcare capital revenues	\$119,471	\$144,366	\$346,440	\$378,335	
Reported gross profit	\$153,122	\$138,006	\$443,495	\$404,240	
Impact of the SYSTEM 1 Rebate Program	—	—	(21,500) —	
Adjusted gross profit	\$153,122	\$138,006	\$421,995	\$404,240	
Reported gross profit percentage	40.3	% 38.9	%41.3	% 39.8	%
Impact of the SYSTEM 1 Rebate Program	—	% —	%(1.2)%—	%
Adjusted gross profit percentage	40.3	% 38.9	%40.1	% 39.8	%
Reported operating income	\$67,140	\$53,724	\$177,719	\$148,268	
Impact of the SYSTEM 1 Rebate Program and class action settlement	(15,800) —	(37,300) —	
Adjusted operating income	\$51,340	\$53,724	\$140,419	\$148,268	
Reported Healthcare operating income	\$45,478	\$33,951	\$110,355	\$88,213	
Impact of the SYSTEM 1 Rebate Program and class action settlement	(15,800) —	(37,300) —	
Adjusted Healthcare operating income	\$29,678	\$33,951	\$73,055	\$88,213	
Reported income tax expense	\$15,174	\$17,443	\$49,166	\$48,189	
Impact of the SYSTEM 1 Rebate Program and class action settlement	(6,162) —	(14,547) —	
Adjusted income tax expense	\$9,012	\$17,443	\$34,619	\$48,189	
Reported selling, general and administrative	\$75,953	\$73,992	\$236,767	\$227,583	
Impact of the SYSTEM 1 class action settlement	15,800	—	15,800	—	
Adjusted selling, general and administrative	\$91,753	\$73,992	\$252,567	\$227,583	
Reported effective income tax rate	24.0	% 34.1	%29.3	% 34.4	%
Impact of the SYSTEM 1 Rebate Program and class action settlement	(5)%—	%(2.8)%—	%
Adjusted effective income tax rate	19.0	% 34.1	%26.5	% 34.4	%

Results of Operations

In the following subsections, we discuss our earnings and the factors affecting them for the third quarter and the first nine months of fiscal 2013 compared with the same fiscal 2012 periods. We begin with a general overview of our

operating results and then separately discuss earnings for our operating segments.

Table of Contents

Revenues. The following tables compare our revenues for the three and nine months ended December 31, 2012 to the revenues for the three and nine months ended December 31, 2011:

(dollars in thousands)	Three Months Ended December 31,		Change	Percent Change	
	2012	2011			%
Total revenues	\$380,405	\$355,215	\$25,190	7.1	%
Revenues by type:					
Capital equipment revenues	147,068	165,290	(18,222)	(11.0)	%
Consumable revenues	96,654	74,113	22,541	30.4	%
Service revenues	136,683	115,812	20,871	18.0	%
Revenues by geography:					
United States revenues	281,411	263,540	17,871	6.8	%
International revenues	98,994	91,675	7,319	8.0	%
(dollars in thousands)	Nine Months Ended December 31,		Change	Percent Change	
	2012	2011			%
Total revenues	\$1,073,686	\$1,016,561	\$57,125	5.6	%
Revenues by type:					
Capital equipment revenues	435,162	439,134	(3,972)	(0.9)	%
Consumable revenues	253,963	225,784	28,179	12.5	%
Service revenues	384,561	351,643	32,918	9.4	%
Revenues by geography:					
United States revenues	815,604	766,011	49,593	6.5	%
International revenues	258,082	250,550	7,532	3.0	%

Quarter over Quarter Comparison

Revenues increased \$25.2 million, or 7.1%, to \$380.4 million for the quarter ended December 31, 2012, as compared to \$355.2 million for the same quarter prior year period. The increase is primarily attributable to the recent business acquisitions partially offset by the expected post-transition decline in SYSTEM 1E unit sales and SYSTEM 1 consumable volumes. Capital equipment revenues of \$147.1 million in the third quarter of fiscal 2013 represent a 11.0% decrease over the third quarter of fiscal 2012 driven by lower capital equipment revenues in the Healthcare segment due to the expected post-transition decline in SYSTEM 1E units. Consumable revenues increased 30.4% for the quarter ended December 31, 2012, as compared to the prior year quarter, primarily driven by acquisitions which combined with growth in other consumables more than offset the declines in SYSTEM 1 consumables. Service revenues increased 18.0% in the third quarter of fiscal 2013 primarily driven by the acquisition of the instrument repair businesses, Spectrum and TRE and growth in other service offerings.

United States revenues increased \$17.9 million, or 6.8%, to \$281.4 million for the quarter ended December 31, 2012, as compared to \$263.5 million for the same prior year quarter. The increase is primarily attributable to the recent business acquisitions and is partially offset by the decline in SYSTEM 1E unit sales and SYSTEM 1 consumable volumes.

International revenues increased \$7.3 million, or 8.0%, to \$99.0 million for the quarter ended December 31, 2012, as compared to \$91.7 million for the same prior year quarter. This increase is attributable to the recent acquisition of US Endoscopy and revenue growth in the Asia Pacific region and Canada, partially offset by declines in the European and Latin American regions.

Table of Contents

First Nine Months over First Nine Months Comparison

Revenues increased \$57.1 million or 5.6% to \$1,073.7 million for the first nine months of fiscal 2013, as compared to \$1,016.6 million for the same prior year period. The increase is partially attributable to the fiscal 2013 second quarter SYSTEM 1 Rebate Program adjustment of \$20.4 million. Adjusted revenues for the first nine months, excluding the impact of the adjustment related to the SYSTEM 1 Rebate Program, were \$1,053.3 million, a 3.6% increase over the same prior year period (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). Capital equipment revenues for the first nine months of fiscal 2013 decreased \$4.0 million or 0.9% compared to the prior year period. Capital equipment revenues for the first nine months of fiscal 2013 were favorably impacted by the \$20.4 million adjustment related to the SYSTEM 1 Rebate Program. Adjusted capital equipment revenues for the first nine months of fiscal 2013 were \$414.8 million, a 5.6% decrease over the first nine months of fiscal 2012 driven by the expected post-transition decline in SYSTEM 1E unit sales compared to the prior year (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). Consumable revenues for the first nine months of fiscal 2013 increased 12.5% over the first nine months of fiscal 2012 as declines in SYSTEM 1 consumable volumes were more than offset by increases within the Healthcare segment, driven largely by recent acquisitions, and within the Life Sciences business segment. Service revenues during the first nine months of fiscal 2013 increased 9.4% over the first nine months of fiscal 2012 primarily driven by the recent acquisition of the instrument repair businesses, Spectrum and TRE and other service offerings.

United States revenues for the first nine months of fiscal 2013 were \$815.6 million, an increase of \$49.6 million or 6.5% over the the first nine months of fiscal 2012 revenues of \$766.0 million. A portion of the increase is attributable to the fiscal 2013 second quarter SYSTEM 1 Rebate Program adjustment of \$20.4 million. Adjusted United States revenues for the first nine months, excluding the impact of the \$20.4 million adjustment related to the SYSTEM 1 Rebate Program, were \$795.2 million, an increase of \$29.2 million or 3.8% over the first nine months of fiscal 2012 (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). United States revenues reflect a decline in capital equipment revenues resulting primarily from the expected post-transition SYSTEM 1E unit sales which was offset by increased consumable and service revenues from our recent acquisitions and increased revenues from other products.

International revenues for the first nine months of fiscal 2013 were \$258.1 million, an increase of 3.0% over the first nine months of fiscal 2012 revenues of \$250.6 million. This increase is attributable to the recent acquisition of US Endoscopy and revenue growth in the Asia Pacific region and Canada, partially offset by declines in the European and Latin American regions.

Revenues by segment are further discussed in the section of MD&A titled, "Business Segment Results of Operations."

Gross Profit. The following tables compare our gross profit for the three and nine months ended December 31, 2012 to the three and nine months ended December 31, 2011:

(dollars in thousands)	Three Months Ended December 31,		Change	Percent Change	
	2012	2011			
Gross profit:					
Product	\$104,039	\$93,427	\$10,612	11.4	%
Service	49,083	44,579	4,504	10.1	%
Total gross profit	\$153,122	\$138,006	\$15,116	11.0	%
Gross profit percentage:					
Product	42.7	% 39.0	%		
Service	35.9	% 38.5	%		
Total gross profit percentage	40.3	% 38.9	%		

Table of Contents

(dollars in thousands)	Nine Months Ended December 31,		Change	Percent Change	
	2012	2011			
Gross profit:					
Product	\$296,814	\$262,704	\$34,110	13.0	%
Service	146,681	141,536	5,145	3.6	%
Total gross profit	\$443,495	\$404,240	\$39,255	9.7	%
Gross profit percentage:					
Product	43.1	% 39.5	%		
Service	38.1	% 40.2	%		
Total gross profit percentage	41.3	% 39.8	%		

Our gross profit percentage is affected by the volume, pricing, and mix of sales of our products and services, as well as the costs associated with the products and services that are sold. Gross profit percentage for the third quarter of fiscal 2013 amounted to 40.3% as compared to the third quarter of fiscal 2012 gross profit percentage of 38.9%. Gross margin percentage was positively impacted by acquisitions (110 basis points) and pricing (100 basis points) and negatively impacted by the SYSTEM 1 and SYSTEM 1E transition (50 basis points) and foreign currency fluctuations (20 basis points.)

Gross profit percentage for the first nine months of fiscal 2013 was 41.3% compared to the gross profit percentage in the first nine months of fiscal 2012 of 39.8%. The primary driver of the increase in gross margin percentage is the positive impact of the \$21.5 million SYSTEM 1 Rebate Program adjustment during the fiscal 2013 second quarter. The adjusted gross profit percentage in the first nine months of fiscal 2013, excluding the impact of the \$21.5 million revenue and cost of goods sold adjustments related to the SYSTEM 1 Rebate Program during the second quarter, was 40.1%, an increase of 30 basis points over the gross profit percentage of 39.8% during the first nine months of fiscal 2012 (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). Other key factors impacting the gross margin percentage in the first nine months of fiscal 2013 include the negative impact of the SYSTEM 1 and SYSTEM 1E transition (110 basis points) and the positive impact of acquisitions (50 basis points), pricing (60 basis points) and foreign currency fluctuations (40 basis points).

Operating Expenses. The following tables compare our operating expenses for the three and nine months ended December 31, 2012 to the three and nine months ended December 31, 2011:

(dollars in thousands)	Three Months Ended December 31,		Change	Percent Change	
	2012	2011			
Operating expenses:					
Selling, general, and administrative	\$75,953	\$73,922	\$2,031	2.7	%
Research and development	10,415	9,196	1,219	13.3	%
Restructuring expenses	(386) 1,164	(1,550) NM	
Total operating expenses	\$85,982	\$84,282	\$1,700	2.0	%
NM - Not meaningful.					

(dollars in thousands)	Nine Months Ended December 31,		Change	Percent Change	
	2012	2011			
Operating expenses:					
Selling, general, and administrative	\$236,767	\$227,583	\$9,184	4.0	%
Research and development	29,579	26,867	2,712	10.1	%
Restructuring expenses	(570) 1,522	(2,092) NM	
Total operating expenses	\$265,776	\$255,972	\$9,804	3.8	%

Significant components of total selling, general, and administrative expenses (“SG&A”) are compensation and benefit costs, fees for professional services, travel and entertainment, facilities costs, and other general and administrative expenses. SG&A increased 2.7% in the third quarter of fiscal 2013 over the third quarter of fiscal 2012, and increased 4.0% in the nine months of fiscal 2013 over the first nine months of fiscal 2012. During the third quarter of fiscal 2013, we adjusted the liability related to the SYSTEM 1 class action settlement. The pre-tax adjustment of \$15.8 million was recorded as a reduction to operating expenses. Adjusted SG&A expenses, excluding the impact of the SYSTEM 1 class action settlement for the third quarter and

Table of Contents

and nine months of fiscal 2013 were \$91.8 million and \$252.6 million, respectively (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). Fiscal 2013 third quarter SG&A includes \$2.1 million of transaction costs and incremental amortization of acquired intangible assets of \$4 million associated with the recent acquisitions. For the first nine months of fiscal 2013, SG&A includes \$5.7 million of transaction costs and incremental amortization of acquired intangible assets of \$7.3 million associated with the recent acquisitions. SG&A also increased due to the operating expenses incurred within the operations of recently acquired businesses. For the three month period ended December 31, 2012, research and development expenses increased 13.3% over the same prior year period. The increase is attributable to expenses for research and development incurred by the recently acquired US Endoscopy. For the nine months of fiscal 2013, research and development expenses were \$29.6 million, representing an increase of 10.1% compared to the same fiscal 2012 period. The majority of the increase is attributable to expenses for research and development incurred by the recently acquired US Endoscopy. Research and development expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations. During the first nine months of fiscal 2013, our investments in research and development continued to be focused on, but were not limited to, enhancing capabilities of sterile processing combination technologies, surgical products and accessories, and the areas of emerging infectious agents such as Prions and Nanobacteria. Restructuring expenses incurred during the three and nine months of fiscal 2013 and fiscal 2012 related to previously announced restructuring plans. The following tables summarize our total pre-tax restructuring expenses for the third quarter of fiscal 2013 and fiscal 2012:

(dollars in thousands)	Fiscal 2010 Restructuring Plan	
	2012	2011 (1)
Three Months Ended December 31,		
Severance and other compensation related costs	\$(386)\$7
Asset impairment and accelerated depreciation	—	1,157
Lease termination obligation and other	—	3
Total restructuring charges	\$(386)\$1,167

(1) Includes \$3 in charges recorded in cost of revenues on Consolidated Statements of Income for fiscal 2012.

The following table summarizes our total pre-tax restructuring expenses for the first nine months of fiscal 2013 and fiscal 2012:

(dollars in thousands)	Fiscal 2010 Restructuring Plan		Fiscal 2008 Restructuring Plan		Total	
	2012	2011 (1)	2012	2011	2012	2011 (1)
Nine Months Ended December 31,						
Severance and other compensation related costs	\$(553)\$(73)\$—	\$—	\$(553)\$(73
Product rationalization	—	335	—	—	—	335
Asset impairment and accelerated depreciation	(17)1,341	—	—	(17)1,341
Lease termination obligation and other	—	3	—	(152)—	(149
Total restructuring charges	\$(570)\$1,606	\$—	\$(152)\$(570)\$1,454

(1) Includes \$(68) in charges recorded in cost of revenues on Consolidated Statements of Income for fiscal 2012.

Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within "Accrued payroll and other related liabilities" and "Accrued expenses and other." The following table summarizes our liabilities related to these restructuring activities:

Table of Contents

(dollars in thousands)	Fiscal 2010 Restructuring Plan			
	March 31, 2012	Fiscal 2013 Provision (1)	Payments/ Impairments (2)	December 31, 2012
Severance and termination benefits	\$659	\$ (553)) \$326	\$432
Asset impairments and accelerated depreciation	—	(17)) 17	—
Lease termination obligations	947	—	(791)) 156
Other	76	—	(76)) —
Total	\$1,682	\$ (570)) \$ (524)) \$588

(1) Includes curtailment benefit of \$495 related to International defined benefit plan. Additional information is included in note 9, "Benefit Plans."

(2) Certain amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Non-Operating Expenses, Net. Non-operating expense, net consists of interest expense on debt, offset by interest earned on cash, cash equivalents, short-term investment balances, and other miscellaneous expense. The following table compares our non-operating expense, net for the three and nine month periods ended December 31, 2012 and December 31, 2011:

(dollars in thousands)	Three Months Ended December 31,		
	2012	2011	Change
Non-operating expenses, net:			
Interest expense	\$4,207	\$3,005	\$1,202
Interest income and miscellaneous expense	(338)) (373)) 35
Non-operating expenses, net	\$3,869	\$2,632	\$1,237

(dollars in thousands)	Nine Months Ended December 31,		
	2012	2011	Change
Non-operating expenses, net:			
Interest expense	\$10,586	\$9,083	\$1,503
Interest income and miscellaneous expense	(629)) (948)) 319
Non-operating expenses, net	\$9,957	\$8,135	\$1,822

Interest expense during the three and nine month fiscal 2013 periods increased due to higher outstanding borrowings. Interest income and miscellaneous expense is immaterial.

Income Tax Expense. The following table compares our income tax expense and effective income tax rates for the three and nine months ended December 31, 2012 to the three and nine months ended December 31, 2011:

(dollars in thousands)	Three Months Ended December 31,		Change	Percent Change
	2012	2011		
Income tax expense	\$15,174	\$17,443	\$ (2,269)) (13.0)%
Effective income tax rate	24.0	% 34.1	%	

(dollars in thousands)	Nine Months Ended December 31,		Change	Percent Change
	2012	2011		
Income tax expense	\$49,166	\$48,189	\$977	2.0%
Effective income tax rate	29.3	% 34.4	%	

Income tax expense includes United States federal, state and local, and foreign income taxes, and is based on reported pre-tax income. The effective income tax rates for continuing operations for the three and nine months ended

December 31, 2012 were 24.0% and 29.3% compared with 34.1% and 34.4% for the same prior year periods. During the first nine months of fiscal 2013, we benefited from higher projected income in lower rate tax jurisdictions, a large favorable discrete item adjustment due

Table of Contents

to the realization of a deduction related to the closure of our Swiss manufacturing operations, and other discrete item adjustments.

We record income tax expense during interim periods based on our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. We analyze various factors to determine the estimated annual effective income tax rate, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carryforwards, and available tax planning alternatives.

Business Segment Results of Operations. We operate in three reportable business segments: Healthcare, Life Sciences, and Isomedix. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs. These costs include executive office costs, Board of Directors compensation, shareholder services and investor relations, external audit fees, and legacy pension and post-retirement benefit costs. Our Annual Report on Form 10-K for the year ended March 31, 2012, dated May 29, 2012, provides additional information regarding each business segment. The following table compares business segment revenues for the three and nine months ended December 31, 2012 and December 31, 2011:

(dollars in thousands)	Three Months Ended December 31,		Change	Percent Change	
	2012	2011			
Revenues:					
Healthcare	\$271,096	\$259,055	\$12,041	4.6	%
Life Sciences	65,043	55,892	9,151	16.4	%
Isomedix	43,392	39,615	3,777	9.5	%
Total reportable segments	379,531	354,562	24,969	7.0	%
Corporate and other	874	653	221	33.8	%
Total Revenues	\$380,405	\$355,215	\$25,190	7.1	%

(dollars in thousands)	Nine Months Ended December 31,		Change	Percent Change	
	2012	2011			
Revenues:					
Healthcare (1)	\$757,430	\$725,455	\$31,975	4.4	%
Life Sciences	180,116	167,675	12,441	7.4	%
Isomedix	133,732	121,617	12,115	10.0	%
Total reportable segments	1,071,278	1,014,747	56,531	5.6	%
Corporate and other	2,408	1,814	594	32.7	%
Total Revenues	\$1,073,686	\$1,016,561	\$57,125	5.6	%

(1) Includes an increase of \$20,400 in the second quarter of fiscal 2013 resulting from the SYSTEM 1 Rebate Program.

Healthcare revenues increased \$12.0 million, or 4.6%, to \$271.1 million for the quarter ended December 31, 2012, as compared to \$259.1 million for the same prior year quarter. This increase is attributable to recent acquisitions, which were partially offset by the expected post-transition decline in SYSTEM 1E unit sales and the decline in SYSTEM 1 consumable volumes. Healthcare revenues for the first nine months of fiscal 2013 increased \$32.0 million, or 4.4% to \$757.4 million, as compared to \$725.5 million for the first nine months of fiscal 2012. The increase is partially attributable to the fiscal 2013 second quarter SYSTEM 1 Rebate Program adjustment of \$20.4 million. Adjusted Healthcare revenues for the first nine months of fiscal 2013, excluding the impact of the adjustment made in the same period related to the SYSTEM 1 Rebate Program, were \$737.0 million, representing an increase of 1.6% compared to the first nine months of fiscal 2012 (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures).

The increase in adjusted revenue is attributable to the addition of consumable revenues and service revenues from our recent acquisitions. These increases were partially offset by the expected post-transition decline in SYSTEM 1E unit sales and the decline in SYSTEM 1 consumable volumes. At December 31, 2012, the Healthcare segment's backlog amounted to \$141.3 million, increasing \$5.5 million, or 4.1%, compared to the backlog of \$135.8 million at December 31, 2011. Healthcare backlog increased \$38.8 million, or 37.9%, compared to the backlog of \$102.5 million at March 31, 2012.

Life Sciences revenues increased \$9.2 million, or 16.4%, to \$65.0 million for the quarter ended December 31, 2012, as compared to \$55.9 million for the same prior year quarter. The increase in Life Sciences revenues was attributable to increases

Table of Contents

in capital equipment, consumable and service revenues. Life Science revenues for the first nine months of fiscal 2013 increased \$12.4 million or 7.4% to \$180.1 million as compared to \$167.7 million for the first nine months of fiscal 2012, driven by growth in capital equipment, consumable and service revenues. At December 31, 2012, the Life Sciences segment's backlog amounted to \$49.6 million, increasing \$4.6 million, or 10.3%, compared to the backlog of \$45.0 million at December 31, 2011. Life Sciences backlog decreased by \$0.5 million, or 0.9%, compared to the backlog of \$50.1 million at March 31, 2012.

Isomedix revenues increased \$3.8 million, or 9.5%, to \$43.4 million for the quarter ended December 31, 2012, as compared to \$39.6 million for the same prior year quarter. Isomedix revenues for the first nine months of fiscal 2013 increased \$12.1 million, or 10.0%, to \$133.7 million as compared to \$121.6 million for the first nine months of fiscal 2012. Revenues were favorably impacted by increased demand from our medical device Customers, as well as the acquisition of Biotest in March 2012. Biotest provides validation services to our Customers with lab operations in Minneapolis, Minnesota.

The following tables compare our business segment operating results for the three and nine months ended December 31, 2012 to the three and nine months ended December 31, 2011:

(dollars in thousands)	Three Months Ended December 31,		Change	Percent Change	
	2012	2011			
Operating income (loss):					
Healthcare (2)	\$45,478	\$33,951	\$11,527	34.0	%
Life Sciences	12,798	10,297	2,501	24.3	%
Isomedix	11,103	11,750	(647)	(5.5))%
Total reportable segments	69,379	55,998	13,381	23.9	%
Corporate and other	(2,239)	(2,274)	35	(1.5))%
Total operating income (loss)	\$67,140	\$53,724	\$13,416	25.0	%

(2) Includes an increase of \$15,800 in the third quarter of fiscal 2013 resulting from the SYSTEM 1 class action settlement.

(dollars in thousands)	Nine Months Ended December 31,		Change	Percent Change	
	2012	2011			
Operating Income (loss):					
Healthcare (3)	\$110,355	\$88,213	\$22,142	25.1	%
Life Sciences	35,201	30,820	4,381	14.2	%
Isomedix	39,348	35,924	3,424	9.5	%
Total reportable segments	184,904	154,957	29,947	19.3	%
Corporate and other	(7,185)	(6,689)	(496)	7.4	%
Total Operating Income (loss)	\$177,719	\$148,268	\$29,451	19.9	%

(3) Includes an increase of \$37,300 in the fiscal 2013 period resulting from the SYSTEM 1 Rebate Program and class action settlement.

Segment operating income is calculated as the segment's gross profit less direct expenses and indirect cost allocations, which results in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. Corporate cost allocations are based on each segment's percentage of revenues, headcount, or other variables in relation to those of the total Company. In addition, the Healthcare segment is responsible for the management of all but one manufacturing facility and uses standard cost to sell products to the Life Sciences segment. Corporate and other includes the revenues, gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits, as previously discussed.

The Healthcare segment's operating income increased \$11.5 million to \$45.5 million for the third quarter of fiscal 2013 as compared to \$34.0 million in the same prior year period. The increase is attributable to the fiscal 2013 third quarter SYSTEM 1 class action adjustment of \$15.8 million. Adjusted Healthcare operating income, excluding the impact of the adjustment related to the SYSTEM 1 class action adjustment during the quarter, was \$29.7 million, a decrease of

\$4.3 million or 12.6% compared to the same prior year quarter (see subsection of MD&A titled, "Non-GAAP Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). The Healthcare segment's operating income for the first nine months of fiscal 2013 increased \$22.1 million to \$110.4 million as compared to \$88.2 million for the first nine months of fiscal 2012. The increase is attributable to the fiscal 2013 second quarter SYSTEM 1 Rebate Program adjustment of \$21.5 million and the fiscal 2013 third quarter SYSTEM 1 class action settlement of \$15.8 million. Adjusted Healthcare operating income, excluding the impact of the adjustments during the period, was \$73.1 million, a decrease of \$15.2 million or 17.2% compared to the same prior year period (see subsection of MD&A titled, "Non-GAAP

Table of Contents

Financial Measures" for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). The decline in adjusted Healthcare operating income reflects the impact of the expected post-transition decline in SYSTEM 1E unit sales, decline in SYSTEM 1 consumable volumes and expenses related to the recent acquisitions.

The Life Sciences segment's operating income increased \$2.5 million, or 24.3%, to \$12.8 million for the third quarter of fiscal 2013 as compared to \$10.3 million for the same prior year period. The Life Sciences segment's operating income for the first nine months of fiscal 2013 increased by \$4.4 million or 14.2% to \$35.2 million as compared to \$30.8 million in the first nine months of fiscal 2012. The segment's operating margin was 19.7% for the third quarter of fiscal 2013 compared to 18.4% for the third quarter of fiscal 2012. The segment's operating margin was 19.5% for the first nine months of fiscal 2013 compared to 18.4% for the first nine months of fiscal 2012. The increased operating margins in both the third quarter and the first nine months of fiscal 2013 is primarily attributable to higher revenues.

The Isomedix segment's operating income decreased \$0.6 million or 5.5% to \$11.1 million for the third quarter of fiscal 2013 as compared to \$11.8 million for the same prior year period. The decrease was primarily attributable to new capacity brought online during the quarter. The Isomedix segment's operating income for the first nine months of fiscal 2013 increased \$3.4 million or 9.5% to \$39.3 million as compared to \$35.9 million in the first first nine months of fiscal 2012, reflecting the benefits of increased revenues and improved operating efficiencies. The Isomedix operating margin was 25.6% for the third quarter of fiscal 2013 compared to 29.7% in the same prior year period; while the operating margin was 29.4% in the first nine months of fiscal 2013 compared to 29.5% in the first nine months of fiscal 2012.

Liquidity and Capital Resources

The following table summarizes significant components of our cash flows for the nine months ended December 31, 2012 and 2011:

(dollars in thousands)	Nine Months Ended December 31,	
	2012	2011
Operating activities:		
Net income	\$ 118,596	\$ 91,944
Non-cash items	77,006	73,626
Change in Accrued SYSTEM 1 Rebate Program and class action settlement	(63,516)	(27,449)
Changes in operating assets and liabilities	48,850	(25,282)
Net cash provided by operating activities	\$ 180,936	\$ 112,839
Investing activities:		
Purchases of property, plant, equipment, and intangibles, net	\$(63,878)	\$(54,238)
Proceeds from the sale of property, plant, equipment, and intangibles	29	—
Investments in businesses, net of cash acquired	(399,415)	(22,269)
Net cash used in investing activities	\$(463,264)	\$(76,507)
Financing activities:		
Proceeds from the issuance of long-term obligations	\$ 100,000	\$—
Proceeds under credit facilities, net	210,890	—
Repurchases of common shares	(7,893)	(56,751)
Deferred financing fees and debt issuance costs	(1,581)	—
Cash dividends paid to common shareholders	(32,045)	(28,751)
Stock option and other equity transactions, net	14,517	3,749
Tax benefit from stock options exercised	2,161	816
Net cash provided by (used in) in financing activities	\$ 286,049	\$ (80,937)
Debt-to-total capital ratio	36.2	% 21.3 %

Free cash flow	\$117,087	\$58,601
----------------	-----------	----------

Net Cash Provided By Operating Activities –The net cash provided by our operating activities was \$180.9 million for the first nine months of fiscal 2013 as compared with \$112.8 million for the first nine months of fiscal 2012. The increase in net cash provided by operating activities in fiscal 2013 is attributable to a decrease in cash needed to fund operating assets and liabilities and the cash benefit from a tax deduction related to the closure of our Swiss manufacturing operations.

Table of Contents

Net Cash Used In Investing Activities – The net cash we used in investing activities totaled \$463.3 million for the first nine months of fiscal 2013 compared with \$76.5 million for the first nine months of fiscal 2012. The following discussion summarizes the significant changes in our investing cash flows for the first nine months of fiscal 2013 and fiscal 2012:

Purchases of property, plant, equipment, and intangibles, net – Capital expenditures were \$63.9 million for the first nine months of fiscal 2013 as compared to \$54.2 million during the same prior year period.

Investment in business, net of cash acquired – During the first nine months of fiscal 2013, we used \$399.4 million in cash for the recent acquisitions of US Endoscopy, Spectrum, TRE and VTS.

Net Cash Provided By (Used In) Financing Activities – The net cash provided in financing activities amounted to \$286.0 million for the first nine months of fiscal 2013 compared with net cash used in financing activities of \$80.9 million for the first nine months of fiscal 2012. The following discussion summarizes the significant changes in our financing cash flows for the first nine months of fiscal 2013 and fiscal 2012:

Proceeds from the issuance of long-term obligations – Proceeds of \$100 million were raised from the issuance of private placement debt. These borrowings were used primarily for the repayment of existing credit facility debt.

Proceeds under credit facilities, net – As of the end of the first nine months of fiscal 2013, we had outstanding borrowings of \$210.9 million under our credit facility that were used to partially fund the recent acquisitions.

Repurchases of common shares – During the first nine months of fiscal 2013, we repurchased 201,349 of our common shares and obtained 51 of our common shares in connection with stock based compensation awards for an aggregate amount of \$7.9 million. During the same period in fiscal 2012, we paid for the repurchase of 1,851,510 of our common shares and obtained 22,927 of our common shares in connection with stock based compensation award programs for an aggregate amount of \$56.8 million.

Deferred financing fees and debt issuance costs – During fiscal 2013, we paid fees of \$1.6 million related to the issuance of new notes in connection with the December 2012 Private Placement and the amendment and restatement of our revolving credit facility.

Cash dividends paid to common shareholders – During the first nine months of fiscal 2013, we paid total cash dividends of \$32.0 million, or \$0.55 per outstanding common share. During the first nine months of fiscal 2012, we paid total cash dividends of \$28.8 million, or \$0.49 per outstanding common share.

Stock option and other equity transactions, net – We receive cash for issuing common shares under our various employee stock option programs. During the first nine months of fiscal 2013 and fiscal 2012, we received cash proceeds totaling \$14.5 million and \$3.7 million, respectively, under these programs.

Cash Flow Measures. Free cash flow was \$117.1 million in the first nine months of fiscal 2013 compared to \$58.6 million in the prior year first nine months due to a decrease in cash needed to fund operating assets and liabilities and the cash benefit from a tax deduction related to the closure of our Swiss manufacturing operations (see subsection of MD&A titled, "Non-GAAP Financial Measures", for additional information and related reconciliation of non-GAAP financial measures to the most comparable GAAP measures). Our debt-to-total capital ratio was 36.2% at December 31, 2012 and 21.3% at December 31, 2011.

Sources of Credit and Contractual and Commercial Commitments. Information related to our sources of credit and contractual and commercial commitments is included in our Annual Report on Form 10-K for the year ended March 31, 2012, dated May 29, 2012. Our commercial commitments were approximately \$47.0 million at December 31, 2012, reflecting a net increase of \$8.7 million in surety bonds and other commercial commitments from March 31, 2012. We amended and restated our credit facility on April 13, 2012 and amended it again on October 12, 2012 to increase the maximum aggregate borrowing limit (as amended, the "Facility"). The maximum aggregate

borrowing limit under the Facility is now \$400 million. The maximum aggregate borrowing limit is reduced by outstanding borrowings and letters of credit issued under a sub-limit within the Facility. There were \$210.9 million in outstanding borrowings and no outstanding letters of credit at December 31, 2012. During December 2012, the Company issued \$100 million in senior notes in a private placement and committed to issue and received commitments to purchase another \$100 million notes from the same purchasers in February, 2013.

Cash Requirements. Currently, we intend to use our existing cash and cash equivalent balances, cash generated from operations, and our existing credit facilities for short-term and long-term capital expenditures and our other liquidity needs. We believe that these amounts will be sufficient to meet working capital needs, capital requirements, and commitments for at least the next twelve months. However, our capital requirements will depend on many uncertain factors, including our rate of sales growth, our Customers' acceptance of our products and services, the costs of obtaining adequate manufacturing capacities, the timing and extent of our research and development projects, and changes in our operating expenses. To the extent that our existing sources of cash are not sufficient to fund our future activities, we may need to raise additional funds through additional

Table of Contents

borrowings or selling equity securities. We cannot assure you that we will be able to obtain additional funds on terms favorable to us, or at all.

Critical Accounting Policies, Estimates, and Assumptions

Information related to our critical accounting policies, estimates, and assumptions is included in our Annual Report on Form 10-K for the year ended March 31, 2012, dated May 29, 2012. Our critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2012 with the exception of the estimation of the SYSTEM 1 Rebate Program and class action settlement liabilities.

SYSTEM 1 Rebate Program and Class Action Settlement

The SYSTEM 1 Rebate Program (the “Rebate Program”) was initially recognized during the first quarter of fiscal 2011. The rebate portion of the Rebate Program was recognized as contra-revenue consistent with other returns and allowances offered to Customers. The estimated costs to facilitate the disposal of the returned SYSTEM 1 processors portion of the Rebate Program were recognized as cost of revenues. Both components are recorded as current liabilities. The key assumptions involved in the estimates associated with the Rebate Program included: the number and age of SYSTEM 1 processors eligible for rebates under the Rebate Program, the number of Customers that would elect to participate in the Rebate Program, the proportion of Customers that would choose each rebate option, and the estimated per unit costs of disposal.

The Rebate Program ended August 2, 2012. Through December 31, 2012, Customers have utilized or committed to utilize rebates totaling approximately \$66.6 million on orders placed since the initiation of the Rebate Program. Additional Customer orders utilizing rebates are not anticipated although exceptions can be made at the discretion of the Company and existing orders may be modified or canceled by Customers. Remaining disposal costs are based on the actual costs experienced to date.

During the second quarter of fiscal 2013, we adjusted the liability related to the SYSTEM 1 Rebate Program. The total pre-tax adjustment was \$21.5 million, of which \$20.4 million was recorded as an increase to revenue for the Customer Rebate portion, and \$1.1 million was recorded as a reduction to cost of revenues related to the disposal portion of the liability. This adjustment resulted primarily from a lower number of eligible Customers electing to participate in the Rebate Program than previously estimated. The remaining recorded accrual is \$4.3 million as of December 31, 2012.

The SYSTEM 1 class action settlement was initially recognized during the third quarter of fiscal 2011. The claim submission deadline was December 31, 2012. As a result, during the third quarter of fiscal 2013, we adjusted the liability related to the SYSTEM 1 class action settlement. The pretax adjustment of \$15.8 million, was recorded as a reduction to operating expenses. The remaining recorded accrual is \$1.2 million as of December 31, 2012 and is based on actual claims submitted.

Contingencies

We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.

We record a liability for such contingencies to the extent we conclude that their occurrence is both probable and estimable. We consider many factors in making these assessments, including the professional judgment of experienced members of management and our legal counsel. We have made estimates as to the likelihood of unfavorable outcomes and the amounts of such potential losses. In our opinion, the ultimate outcome of these proceedings and claims is not anticipated to have a material adverse affect on our consolidated financial position, results of operations, or cash flows. However, the ultimate outcome of proceedings, government investigations, and claims is unpredictable and actual results could be materially different from our estimates. We record expected recoveries under applicable insurance contracts when we are assured of recovery. Refer to Part II, Item 1, “Legal Proceedings” for additional information.

Table of Contents

We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual tax jurisdiction or the closing of a statute of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. The IRS routinely conducts audits of our federal income tax returns. We are no longer subject to United States federal examinations for years before fiscal 2010 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2008. We remain subject to tax authority audits in various other jurisdictions in which we operate. If we prevail in matters for which accruals have been recorded, or are required to pay amounts in excess of recorded accruals, our effective income tax rate in a given financial statement period could be materially impacted.

Additional information regarding our commitments and contingencies is included in note 10 to our consolidated financial statements titled, "Commitments and Contingencies."

International Operations

Since we conduct operations outside of the United States using various foreign currencies, our operating results are impacted by foreign currency movements relative to the U.S. dollar. During the third quarter of fiscal 2013, our revenues were unfavorably impacted by \$0.4 million, or 0.1%, and income before taxes was unfavorably impacted by \$0.9 million, or 1.4%, as a result of foreign currency movements relative to the U.S. dollar. During the first nine months of fiscal 2013, our revenues were unfavorably impacted by \$7.7 million, or 0.7%, and income before taxes was favorably impacted by \$4.2 million, or 2.6%, as a result of foreign currency movements relative to the U.S. dollar.

Forward-Looking Statements

This Form 10-Q may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "outlook," "impact," "potential," "confidence," "improve," "optimistic," "deliver," "comfortable," "trend", and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or interpretation thereof. Other risk factors are described herein and in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any result or the timing of any outcome regarding matters described herein or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, rebate program, transition, cost reductions, business strategies, earnings or revenue trends or future financial results (including without limitation the settlement of the SYSTEM 1 class action litigation and the regulatory matters related to SYSTEM 1E or its accessories). References to products, the consent decree, the transition or rebate program, or the class action settlement, are summaries only and should not be considered the specific terms of the decree, settlement, program or product clearance or literature. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing or costs that leads to erosion of profit margins, (b) the possibility that market demand will not

develop for new technologies, products or applications, or business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation those relating to FDA warning notices or letters, government investigations, the SYSTEM 1E device, the outcome of any pending FDA requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product introductions, affect the production and marketing of existing products or services or otherwise affect Company performance, results, prospects or value, (d) the potential of international unrest, economic downturn or effects of currencies, tax assessments, adjustments or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, (f) the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, including without limitation SYSTEM 1E and accessories thereto, or other results may not be achieved, or that transition, labor, competition, timing, execution,

Table of Contents

regulatory, governmental, or other issues or risks associated with our business, industry or initiatives including, without limitation, the consent decree, and the transition from the SYSTEM 1 processing system and adjustments to related reserves or those matters described in our Form 10-K for the year ended March 31, 2012 and other securities filings, may adversely impact Company performance, results, prospects or value, (g) the possibility that anticipated financial results or benefits of recent acquisitions will not be realized or will be other than anticipated, (h) the effect of the contraction in credit availability, as well as the ability of our Customers and suppliers to adequately access the credit markets when needed, and (i) those risks described in our securities filings including our Annual Report on Form 10-K for the year ended March 31, 2012, and other securities filings.

Availability of Securities and Exchange Commission Filings

We make available free of charge on or through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to these reports as soon as reasonably practicable after we file such material with, or furnish such material to, the Securities Exchange Commission ("SEC.") You may access these documents on the Investor Relations page of our website at <http://www.steris-ir.com>. The information on our website is not incorporated by reference into this report. You may also obtain copies of these documents by visiting the SEC's Public Reference Room at 100 F Street, NE, Washington, D.C. 20549, or by accessing the SEC's website at <http://www.sec.gov>. You may obtain information on the Public Reference Room by calling the SEC at 1-800-SEC-0330.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

In the ordinary course of business, we are subject to interest rate, foreign currency, and commodity risks. Information related to these risks and our management of these exposures is included in Part II, Item 7A, "Quantitative and Qualitative Disclosures about Market Risk," in our Annual Report on Form 10-K for the year ended March 31, 2012, dated May 29, 2012. Our exposures to market risks have not changed materially since March 31, 2012.

ITEM 4. CONTROLS AND PROCEDURES

Under the supervision of and with the participation of our management, including the Principal Executive Officer ("PEO") and Principal Financial Officer ("PFO"), we evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as of the end of the period covered by this Quarterly Report. Based on that evaluation, including the assessment and input of our management, the PEO and PFO concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective.

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934, that occurred during the quarter ended December 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse affect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the FDA-related matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.

As previously disclosed, we received a warning letter (the “warning letter”) from the FDA on May 16, 2008 regarding our SYSTEM 1 sterile processor and the STERIS® 20 sterilant used with the processor (sometimes referred to collectively in the FDA letter and in this Item 1 as the “device”). Among other matters, the warning letter included the FDA's assertion that significant changes or modifications had been made in the design, components, method of manufacture, or intended use of the device beyond the FDA's 1988 clearance, such that the FDA believed a new premarket notification submission (known within FDA regulations as a 510(k) submission) should have been made, and the assertion that our failure to make such a submission resulted in violations of applicable law. On July 30, 2008 (with an Addendum on October 9, 2008), we provided a detailed response contending that the assertions in the warning letter were not correct. On November 4, 2008, we received a letter from the FDA (dated November 3, 2008) in which the FDA stated without elaboration that, after reviewing our response, it disagreed with our position and that a new premarket notification submission was required. After discussions with the FDA regarding the November 3rd letter, we received an additional letter on November 6, 2008 from the FDA. The November 6th letter stated that the intent of the November 3rd letter was to inform us of the FDA's preliminary disagreement with our response to the warning letter and, before finalizing a position, the FDA reiterated that it wanted to meet with us to discuss the Company's response, issues related to the warning letter and next steps to resolve any differences between the Company and the FDA. We thereafter met with the FDA and, on January 20, 2009, we announced that we had submitted to the FDA a new liquid chemical sterilant processing system for 510(k) clearance, and we communicated to Customers that we would continue supporting the existing SYSTEM 1 installed base in the U.S. for at least a two year period from that date.

On December 3, 2009, the FDA provided a notice (“notice”) to healthcare facility administrators and infection control practitioners describing FDA's “concerns about the SYSTEM 1 Processor, components and accessories, and FDA recommendations.” In the notice, among other things, FDA stated its belief that the SYSTEM 1 device had been significantly modified, that FDA had not cleared or approved the modified device, and that FDA had not determined whether the SYSTEM 1 was safe or effective for its labeled claims. The notice further stated that use of a device that does not properly sterilize or disinfect a medical or surgical device poses risks to patients and users, including the transmission of pathogens, exposure to hazardous chemicals and may affect the quality and functionality of reprocessed instruments. The notice stated that FDA was aware of reports of malfunctions of the SYSTEM 1 that had

the potential to cause or contribute to serious injuries to patients, such as infections, or injuries to healthcare staff, such as burns. Included in FDA's December 3, 2009 notice was a recommendation from FDA that if users had acceptable alternatives to meet sterilization and disinfection needs, they should transition to that alternative as soon as possible. After its December 3, 2009 notice, we engaged in extensive discussions with the FDA regarding a comprehensive resolution of this matter. On February 2, 2010, the FDA notified healthcare facility administrators and infection control practitioners that FDA's total recommended time period for transitioning from SYSTEM 1 in the U.S. was 18 months from that date.

On April 5, 2010, we received FDA clearance of the new liquid chemical sterilant processing system (SYSTEM 1E). Also in April 2010 we reached agreement with the FDA on the terms of a consent decree ("Consent Decree"). On April 19, 2010, a Complaint and Consent Decree were filed in the U.S. District Court for the Northern District of Ohio, and on April 20, 2010, the Court approved the Consent Decree. In general, the Consent Decree addresses regulatory matters regarding SYSTEM 1,

Table of Contents

restricts further sales of SYSTEM 1 processors in the U.S., defines certain documentation and other requirements for continued service and support of SYSTEM 1 in the U.S., prohibits the sale of liquid chemical sterilization or disinfection products in the U.S. that do not have FDA clearance, describes various process and compliance matters, and defines penalties in the event of violation of the Consent Decree.

The Consent Decree also provides that we may continue to support our Customers' use of SYSTEM 1 in the U.S., including the sale of consumables, parts and accessories and service for a transition period, not to extend beyond August 2, 2011, subject to compliance with requirements for documentation of the Customer's need for continued support and other conditions and limitations (the "Transition Plan"). This transition period has since been extended by the FDA until August 2, 2012. Our Transition Plan included the "SYSTEM 1 Rebate Program" (the "Rebate Program"). In April 2010, we began to offer rebates to qualifying Customers. Generally, U.S. Customers that purchased SYSTEM 1 processors directly from us or who were users of SYSTEM 1 at the time the Rebate Program was introduced and who returned their units had the option of either a pro-rated cash rebate or rebate toward the future purchase of new STERIS capital equipment (including SYSTEM 1E) or consumable products. In addition, we provided credits for the return of SYSTEM 1 consumables in unbroken packaging and within shelf life and for the unused portion of SYSTEM 1 service contracts. The Rebate Program ended on August 2, 2012. During the second quarter of fiscal year 2013, we adjusted the liability related to the Rebate Program. No further material adjustments are expected.

The Consent Decree has defined the resolution of a number of issues regarding SYSTEM 1, and we believe our actions with respect to SYSTEM 1, including the Transition Plan, were and are not recalls, corrections or removals under FDA regulations. However, there is no assurance that these or other claims will not be brought or that judicial, regulatory, administrative or other legal or enforcement actions, notices or remedies will not be pursued, or that action will not be taken in respect of the Consent Decree, the Transition Plan, SYSTEM 1, or otherwise with respect to regulatory or compliance matters, as described in this Item 1 and in various portions of Item 1A. of Part I of our Annual Report on Form 10-K for the year ended March 31, 2012 dated May 29, 2012.

In December of 2010, we began shipping SYSTEM 1E units after having received FDA clearance for the SYSTEM 1E chemical indicator, which is used in conjunction with the SYSTEM 1E. We also submitted a 510(k) to FDA for an optional spore-based indicator strip for use with SYSTEM 1E. Thereafter, as a result of discussions with FDA, we filed a de novo submission requesting classification of this strip in accordance with Section 513(f)(2) of the Federal Food Drug & Cosmetic Act. The de novo process is part of the initial classification for new devices. This spore-based monitoring strip received FDA clearance on March 30, 2012. This new clearance does not affect the prior clearance of the SYSTEM 1E processor or the SYSTEM 1E chemical indicator.

On February 5, 2010, a complaint was filed by a Customer that claimed to have purchased two SYSTEM 1 devices from STERIS, Physicians of Winter Haven LLC d/b/a Day Surgery Center v. STERIS Corp., Case No.

1:1-cv-00264-CAB (N.D. Ohio). The complaint alleged statutory violations, breaches of various warranties, negligence, failure to warn, and unjust enrichment and Plaintiff sought class certification, damages, and other legal and equitable relief including, without limitation, attorneys' fees and an order requiring STERIS to replace, recall or adequately repair the product and/or to take appropriate regulatory action. On February 7, 2011 we entered into a settlement agreement in which we agreed, among other things, to provide various categories of economic relief for members of the settlement class and not object to plaintiff's counsel's application to the court for attorneys' fees and expenses up to a specified amount. Certification of a settlement class was approved and final approval of the settlement was given by the court in the first quarter of fiscal 2012.

On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results.

Other civil, criminal, regulatory or other proceedings involving our products or services also could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines

or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially affect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the fiscal year ended March 31, 2012: “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factor” titled: “We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters, including the Warning Letter and Consent Decree” and the “Risk Factor” titled “Compliance with the Consent Decree may be more costly and burdensome than anticipated.”

Table of Contents

From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. Additional information regarding our contingencies is included in Item 7 of Part II, titled "Management's Discussion and Analysis of Financial Conditions and Results of Operations, of our Annual Report on Form 10-K for the year ended March 31, 2012 dated with the SEC on May 29, 2012, and in this Form 10-Q in note 10 to our consolidated financial statements titled "Commitments and contingencies."

ITEM 1A. RISK FACTORS

We believe there have been no material changes to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2012, dated May 29, 2012, that would materially affect our business, results of operations, or financial condition.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the third quarter of fiscal 2013, we obtained 50,852 of our common shares in connection with stock based compensation award programs. We also repurchased 157,400 of our shares during the third quarter of fiscal 2013. These repurchases were made pursuant to a single repurchase program which was approved by our Board of Directors and announced on March 14, 2008, authorizing the repurchase of up to \$300.0 million of our common shares. As of December 31, 2012, \$111.6 million in common shares remained authorized for repurchase under this authorization. This common share repurchase authorization does not have a stated maturity date. The following table summarizes the common shares repurchase activity during the third quarter of fiscal 2013 under our common share repurchase program:

	(a) Total Number of Shares Purchased	(b) Average Price Paid Per Share	(c) Total Number of Shares Purchased as Part of Publicly Announced Plans	(d) Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans at Period End
October 1-31	—	\$ —	—	\$116,888
November 1-30	103,400	33.19	103,400	113,457
December 1-31	54,000	33.83	54,000	111,630
Total	157,400	(1) \$ 33.41	(1) 157,400	\$111,630

Does not include 380 shares purchased during the quarter at an average price of \$34.47 per share by the STERIS (1) Corporation 401(k) Plan on behalf of certain executive officers of the Company who may be deemed to be affiliated purchasers.

Table of Contents

ITEM 6. EXHIBITS

Exhibits required by Item 601 of Regulation S-K

Exhibit Number	Exhibit Description
3.1	1992 Amended Articles of Incorporation of STERIS Corporation, as amended on May 14, 1996, November 6, 1996, and August 6, 1998 (filed as Exhibit 3.1 to Form 10-K filed for the fiscal year ended March 31, 2000 (Commission File No. 1-14643), and incorporated herein by reference).
3.2	Amended and Restated Regulations of STERIS Corporation, as amended on July 26, 2007 (filed as Exhibit 3.2 to Form 10-Q for the fiscal quarter ended June 30, 2007 (Commission File No. 1-14643), and incorporated herein by reference).
4.1	Specimen Form of Common Stock Certificate (filed as Exhibit 4.1 to Form 10-K filed for the fiscal year ended March 31, 2002 (Commission File No. 1-14643), and incorporated herein by reference).
10.1	Joinder Supplement to Third Amended and Restated Guaranty of Payment made by United States Endoscopy Group, Inc. and dated October 9, 2012.
10.2	Guaranty Supplement dated October 10, 2012 by United States Endoscopy Group, Inc. and STERIS Corporation.
10.3	Guaranty Supplement dated October 10, 2012 by United States Endoscopy Group, Inc. and STERIS Corporation.
10.4	Amendment No. 1 dated October 12, 2012 to Third Amended and Restated Credit Agreement, dated as of April 13, 2012, among STERIS Corporation, KeyBank National Association as agent for the lenders from time to time party thereto and such lenders.
10.5	Stock Purchase Agreement dated October 16, 2012 between STERIS Corporation, Richard J. and Michelle A. Schultz, individually and as trustees of certain trusts, such trusts and Spectrum Surgical Instruments Corp.
10.6	Joinder Supplement to Third Amended and Restated Guaranty of Payment made by Spectrum Surgical Instruments Corp. and dated October 29, 2012.
10.7	Guaranty Supplement dated October 29, 2012 by Spectrum Surgical Instruments Corp. and STERIS Corporation.
10.8	Guaranty Supplement dated October 29, 2012 by Spectrum Surgical Instruments Corp. and STERIS Corporation.
10.9	Form of Note Purchase Agreements dated as of December 4, 2012, between STERIS Corporation and certain institutional investors.
10.10	Subsidiary Guaranty dated as of December 4, 2012, by certain subsidiaries of STERIS Corporation
10.11	Amendment to Nonqualified Stock Option Agreement

- 10.12 Form of Nonqualified Stock Option Agreement for Nonemployee Directors
- 10.13 Form of Nonqualified Stock Option Agreement for Employees
- 10.14 Form of Nonqualified Stock Option Agreement for Employees
- 15.1 Letter Re: Unaudited Interim Financial Information.
- 31.1 Certification of the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant Section 906 of the Sarbanes-Oxley Act of 2002.
- EX-101 Instance Document.
- EX-101 Schema Document.
- EX-101 Calculation Linkbase Document.
- EX-101 Definition Linkbase Document.
- EX-101 Labels Linkbase Document.
- EX-101 Presentation Linkbase Document.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

STERIS Corporation

/S/ MICHAEL J. TOKICH

Michael J. Tokich

Senior Vice President and Chief Financial Officer

February 8, 2013

Table of Contents

EXHIBIT INDEX

Exhibit Number	Exhibit Description
3.1	1992 Amended Articles of Incorporation of STERIS Corporation, as amended on May 14, 1996, November 6, 1996, and August 6, 1998 (filed as Exhibit 3.1 to Form 10-K filed for the fiscal year ended March 31, 2000 (Commission File No. 1-14643), and incorporated herein by reference).
3.2	Amended and Restated Regulations of STERIS Corporation, as amended on July 26, 2007 (filed as Exhibit 3.2 to Form 10-Q for the fiscal quarter ended June 30, 2007 (Commission File No. 1-14643), and incorporated herein by reference).
4.1	Specimen Form of Common Stock Certificate (filed as Exhibit 4.1 to Form 10-K filed for the fiscal year ended March 31, 2002 (Commission File No. 1-14643), and incorporated herein by reference).
10.1	Joinder Supplement to Third Amended and Restated Guaranty of Payment made by United States Endoscopy Group, Inc. and dated October 9, 2012.
10.2	Guaranty Supplement dated October 10, 2012 by United States Endoscopy Group, Inc. and STERIS Corporation.
10.3	Guaranty Supplement dated October 10, 2012 by United States Endoscopy Group, Inc. and STERIS Corporation.
10.4	Amendment No. 1 dated October 12, 2012 to Third Amended and Restated Credit Agreement, dated as of April 13, 2012, among STERIS Corporation, KeyBank National Association as agent for the lenders from time to time party thereto and such lenders.
10.5	Stock Purchase Agreement dated October 16, 2012 between STERIS Corporation, Richard J. and Michelle A. Schultz, individually and as trustees of certain trusts, such trusts and Spectrum Surgical Instruments Corp.
10.6	Joinder Supplement to Third Amended and Restated Guaranty of Payment made by Spectrum Surgical Instruments Corp. and dated October 29, 2012.
10.7	Guaranty Supplement dated October 29, 2012 by Spectrum Surgical Instruments Corp. and STERIS Corporation.
10.8	Guaranty Supplement dated October 29, 2012 by Spectrum Surgical Instruments Corp. and STERIS Corporation.
10.9	Form of Note Purchase Agreements dated as of December 4, 2012, between STERIS Corporation and certain institutional investors.
10.10	Subsidiary Guaranty dated as of December 4, 2012, by certain subsidiaries of STERIS Corporation
10.11	Amendment to Nonqualified Stock Option Agreement
10.12	Form of Nonqualified Stock Option Agreement for Nonemployee Directors

Edgar Filing: STERIS CORP - Form 10-Q

- 10.13 Form of Nonqualified Stock Option Agreement for Employees
- 10.14 Form of Nonqualified Stock Option Agreement for Employees
- 15.1 Letter Re: Unaudited Interim Financial Information.
- 31.1 Certification of the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant Section 906 of the Sarbanes-Oxley Act of 2002.
- EX-101 Instance Document.
- EX-101 Schema Document.
- EX-101 Calculation Linkbase Document.
- EX-101 Definition Linkbase Document.
- EX-101 Labels Linkbase Document.
- EX-101 Presentation Linkbase Document.